5 |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
leads to |
Reduction, Plasma 17beta-estradiol concentrations |
9 |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
leads to |
Decreased, Mitochondrial fatty acid beta-oxidation |
11 |
AchE Inhibition |
leads to |
ACh Synaptic Accumulation |
16 |
Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways |
leads to |
Altered, Cardiovascular development/function |
17 |
Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways |
leads to |
Up Regulation, CYP1A1 |
18 |
Activation, AhR |
leads to |
Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways |
19 |
Activation, AhR |
leads to |
Up Regulation, CYP1A1 |
23 |
Alkylation, DNA |
leads to |
Increase, Heritable mutations in offspring |
24 |
Alkylation, DNA |
leads to |
N/A, Inadequate DNA repair |
25 |
Alkylation, DNA |
leads to |
Increase, Mutations |
31 |
Agonism, Androgen receptor |
leads to |
Reduction, Gonadotropins, circulating concentrations |
32 |
Agonism, Androgen receptor |
leads to |
Reduction, Testosterone synthesis by ovarian theca cells |
33 |
N/A, Androgen receptor, Antagonism |
leads to |
Altered, Transcription of genes by AR |
35 |
N/A, Androgen receptor, Antagonism |
leads to |
Alteration, Wnt pathway |
36 |
Reduction, Angiogenesis |
leads to |
Impairment, Endothelial network |
43 |
Decrease, Aromatase (Cyp19a1) |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
45 |
Inhibition, Aromatase |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
51 |
Increased Cholinergic Signaling |
leads to |
Decrease, Population trajectory |
59 |
Reduction, Ca and HCO3 transport to shell gland |
leads to |
Reduction, Eggshell thickness |
60 |
Increase, Ca++ (intracellular) |
leads to |
Disruption, Mitochondrial electron transport chain |
61 |
Inhibition, Ca++ ATPase |
leads to |
Increase, Ca++ (intracellular) |
62 |
Decreased, Calcium influx |
leads to |
Impairment, Learning and memory |
66 |
Up Regulation, CD36 |
leads to |
Increase, FA Influx |
67 |
Cell injury/death |
leads to |
Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) |
68 |
Cell injury/death |
leads to |
Activation, Stellate cells |
69 |
Proliferation, Cell proliferation in the absence of cytotoxicity |
leads to |
Hyperplasia, Hyperplasia |
70 |
Induction, Chitin degradation and resorption |
leads to |
Induction, Pre-mature molting |
77 |
Activation, ChREBP |
leads to |
Synthesis, De Novo FA |
82 |
Accumulation, Collagen |
leads to |
N/A, Liver fibrosis |
88 |
N/A, Covalent binding to protein, possibly lysine residue |
leads to |
Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways |
93 |
Production, Critical Metabolites (CGA 330050 and CGA 265307) |
leads to |
Induction, Liver “Dysfunctional” Changes by CGA 330050 |
94 |
Reduction, Cumulative fecundity and spawning |
leads to |
Decrease, Population trajectory |
95 |
Inhibition, Cyclooxygenase activity |
leads to |
Reduction, Prostaglandin E2 concentration |
96 |
Up Regulation, CYP1A1 |
leads to |
Peptide Oxidation |
104 |
Up Regulation, CYP1B1 |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
108 |
Release, Cytokine |
leads to |
Increase, Inflammation |
110 |
Synthesis, De Novo FA |
leads to |
Accumulation, Triglyceride |
116 |
Increase, EcR agonism |
leads to |
Induction, Chitin degradation and resorption |
123 |
Reduction, Eggshell thickness |
leads to |
N/A, Reproductive failure |
125 |
Impairment, Endothelial network |
leads to |
Insufficiency, Vascular |
126 |
Agonism, Estrogen receptor |
leads to |
Altered, Reproductive behaviour |
127 |
Agonism, Estrogen receptor |
leads to |
Impaired development of, Reproductive organs |
128 |
Agonism, Estrogen receptor |
leads to |
Increase, Vitellogenin synthesis in liver |
129 |
Antagonism, Estrogen receptor |
leads to |
Reduction, Vitellogenin synthesis in liver |
132 |
Increase, FA Influx |
leads to |
Accumulation, Triglyceride |
133 |
Activation, FAS |
leads to |
Synthesis, De Novo FA |
135 |
Decrease, Fecundity |
leads to |
Decline, Population |
136 |
N/A, Gap |
leads to |
Reduction, Ca and HCO3 transport to shell gland |
143 |
Reduction, Gonadotropins, circulating concentrations |
leads to |
Reduction, Testosterone synthesis by ovarian theca cells |
144 |
Depletion, GSH |
leads to |
N/A, Oxidative stress |
146 |
Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) |
leads to |
Peptide Oxidation |
147 |
Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) |
leads to |
Up Regulation, TGFbeta1 expression |
154 |
Decreased, HSD17B10 expression |
leads to |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
158 |
Hyperplasia, Hyperplasia |
leads to |
Promotion, Hepatocelluar carcinoma |
159 |
Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 |
leads to |
Induction, Sustained Hepatotoxicity |
164 |
N/A, Inadequate DNA repair |
leads to |
Increase, Mutations |
168 |
N/A, Interferences with SH-/selen-proteins |
leads to |
Depletion, GSH |
169 |
Increase, Liver and splenic hemosiderosis |
leads to |
N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number |
170 |
Induction, Liver “Dysfunctional” Changes by CGA 330050 |
leads to |
Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 |
172 |
Activation, Long term AHR receptor driven direct and indirect gene expression changes |
leads to |
N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
173 |
Activation, LXR |
leads to |
Up Regulation, CD36 |
174 |
Activation, LXR |
leads to |
Activation, ChREBP |
175 |
Activation, LXR |
leads to |
Activation, FAS |
176 |
Activation, LXR |
leads to |
Activation, SCD-1 |
177 |
Activation, LXR |
leads to |
Activation, SREBP-1c |
182 |
N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number |
leads to |
N/A, Cyanosis occurs |
188 |
Disruption, Mitochondrial electron transport chain |
leads to |
Decrease, Mitochondrial ATP production |
189 |
Disruption, Mitochondrial electron transport chain |
leads to |
Increase, ROS production |
190 |
Decreased, Mitochondrial fatty acid beta-oxidation |
leads to |
Accumulation, Fatty acid |
196 |
Abnormal, Morphogenesis |
leads to |
Increased, Lethality |
197 |
Abnormal, Morphogenesis |
leads to |
Increased, Structural malformations |
198 |
Increase, Mortality |
leads to |
Decrease, Fecundity |
199 |
Increase, Mortality |
leads to |
Decline, Population |
200 |
Increased Mortality |
leads to |
Decline, Population |
202 |
Increase, Mutations |
leads to |
Increase, Heritable mutations in offspring |
203 |
Altered, Neuroanatomy |
leads to |
Altered, Neurophysiology |
207 |
N/A, Neurodegeneration |
leads to |
Neuroinflammation |
208 |
Neuroinflammation |
leads to |
N/A, Neurodegeneration |
210 |
N/A, Neuronal dysfunction |
leads to |
Neuroinflammation |
212 |
Decreased, Nitric Oxide |
leads to |
Decreased, Long-term potentiation (LTP) |
213 |
Inhibition, NMDARs |
leads to |
Decreased, Calcium influx |
214 |
Inhibition, NMDARs |
leads to |
Impairment, Learning and memory |
215 |
Inhibition, NMDARs |
leads to |
N/A, Neuronal dysfunction |
228 |
Binding of antagonist, NMDA receptors |
leads to |
Impairment, Learning and memory |
229 |
Binding of antagonist, NMDA receptors |
leads to |
Inhibition, NMDARs |
236 |
Peptide Oxidation |
leads to |
Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) |
239 |
N/A, Oxidative stress |
leads to |
N/A, Neuronal dysfunction |
240 |
Propagation, Oxidative stress |
leads to |
Down Regulation, Gulcose-6-phosphate dehydrogenase |
241 |
Propagation, Oxidative stress |
leads to |
Damaging, Red blood cells; hemolysis |
242 |
N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
leads to |
Altered regulation, Alpha hemoglobin |
243 |
N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
leads to |
Formation, Formation of hemoglobin adducts |
244 |
N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
leads to |
Propagation, Oxidative stress |
245 |
N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
leads to |
Damaging, Red blood cells; hemolysis |
248 |
Bile accumulation, Pathological condition |
leads to |
Activation of specific nuclear receptors, Transcriptional change |
252 |
Reduction, Plasma 17beta-estradiol concentrations |
leads to |
Reduction, Vitellogenin synthesis in liver |
253 |
Reduction, Plasma 17beta-estradiol concentrations |
leads to |
Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
254 |
Increase, Plasma vitellogenin concentrations |
leads to |
Increase, Renal pathology due to VTG deposition |
255 |
Reduction, Plasma vitellogenin concentrations |
leads to |
Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
256 |
demethylation, PPARg promoter |
leads to |
Decrease, Aromatase (Cyp19a1) |
257 |
Decreased, PPAR-alpha activation |
leads to |
Decreased, HSD17B10 expression |
259 |
Decreased, PPAR-beta activation |
leads to |
Decreased, HSD17B10 expression |
260 |
Decreased, PPAR-gamma activation |
leads to |
Decreased, HSD17B10 expression |
261 |
Induction, Pre-mature molting |
leads to |
Decrease, Fecundity |
262 |
Induction, Pre-mature molting |
leads to |
Increase, Mortality |
263 |
Induction, Pre-mature molting |
leads to |
Increased Mortality |
266 |
Feminisation or incomplete development, Primary and accessory male sex organs |
leads to |
N/A, Impairment of reproductive capacity |
268 |
Reduction, Prostaglandin E2 concentration |
leads to |
N/A, Gap |
269 |
Alkylation, Protein |
leads to |
Cell injury/death |
271 |
Alkylation, Protein |
leads to |
Peptide Oxidation |
272 |
Increase, RBC congestion in liver |
leads to |
N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number |
276 |
Production, Reactive oxygen species |
leads to |
Peptide Oxidation |
277 |
Damaging, Red blood cells; hemolysis |
leads to |
Increase, Liver and splenic hemosiderosis |
278 |
Damaging, Red blood cells; hemolysis |
leads to |
N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number |
279 |
Damaging, Red blood cells; hemolysis |
leads to |
Increase, RBC congestion in liver |
280 |
Increase, Renal pathology due to VTG deposition |
leads to |
Altered, Larval development |
282 |
Increase, ROS production |
leads to |
Decreased, Nitric Oxide |
283 |
Increase, ROS production |
leads to |
Increased, Oxidative damage |
284 |
Activation, SCD-1 |
leads to |
Synthesis, De Novo FA |
287 |
Binding, SH-/selen-proteins |
leads to |
N/A, Interferences with SH-/selen-proteins |
294 |
Activation, SREBP-1c |
leads to |
Synthesis, De Novo FA |
295 |
Activation, Stellate cells |
leads to |
Accumulation, Collagen |
296 |
Increased, Structural malformations |
leads to |
Increased, Lethality |
298 |
Induction, Sustained Cell Proliferation |
leads to |
Formation, Liver tumor |
299 |
Induction, Sustained Hepatotoxicity |
leads to |
Induction, Sustained Cell Proliferation |
301 |
Activation/Proliferation, T-cells |
leads to |
N/A, Allergic contact dermatitis on challenge |
302 |
Reduction, Testosterone synthesis by ovarian theca cells |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
303 |
Up Regulation, TGFbeta1 expression |
leads to |
Accumulation, Collagen |
304 |
Up Regulation, TGFbeta1 expression |
leads to |
Activation, Stellate cells |
305 |
TH synthesis, Decreased |
leads to |
T4 in serum, Decreased |
309 |
Thyroperoxidase, Inhibition |
leads to |
TH synthesis, Decreased |
312 |
T4 in serum, Decreased |
leads to |
T4 in neuronal tissue, Decreased |
315 |
Reduction, Vitellogenin synthesis in liver |
leads to |
Reduction, Plasma vitellogenin concentrations |
316 |
Altered, Transcription of genes by AR |
leads to |
Feminisation or incomplete development, Primary and accessory male sex organs |
317 |
Altered, Transcription of genes by AR |
leads to |
Alteration, Wnt pathway |
319 |
Activation of specific nuclear receptors, Transcriptional change |
leads to |
Cholestasis, Pathology |
321 |
Accumulation, Triglyceride |
leads to |
Damaging, Mitochondria |
324 |
N/A, Unknown |
leads to |
Proliferation, Cell proliferation in the absence of cytotoxicity |
329 |
Insufficiency, Vascular |
leads to |
Abnormal, Morphogenesis |
330 |
Binding, VEGF-A |
leads to |
Decreased, VegfR2 |
331 |
Binding, VEGF-A |
leads to |
Inhibition, VegfR2 |
332 |
Production, VEGF-A |
leads to |
Binding, VEGF-A |
333 |
Production, VEGF-A |
leads to |
Decreased, VegfR2 |
334 |
Decreased, VegfR2 |
leads to |
Inhibition, VegfR2 |
335 |
Inhibition, VegfR2 |
leads to |
Reduction, Angiogenesis |
336 |
Increase, Vitellogenin synthesis in liver |
leads to |
Increase, Plasma vitellogenin concentrations |
337 |
Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
leads to |
Reduction, Cumulative fecundity and spawning |
338 |
Alteration, Wnt pathway |
leads to |
Feminisation or incomplete development, Primary and accessory male sex organs |
340 |
Activation, Pre-MIE: Metabolism of AFB1 |
leads to |
Formation, Pro-mutagenic DNA Adducts |
342 |
Increased, Induced Mutations in Critical Genes |
leads to |
Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H |
343 |
Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H |
leads to |
Tumorigenesis, Hepatocellular carcinoma |
344 |
Formation, Pro-mutagenic DNA Adducts |
leads to |
Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H |
345 |
Formation, Pro-mutagenic DNA Adducts |
leads to |
Tumorigenesis, Hepatocellular carcinoma |
346 |
Increased, Induced Mutations in Critical Genes |
leads to |
Tumorigenesis, Hepatocellular carcinoma |
347 |
Decreased, Calcium influx |
leads to |
BDNF, Reduced |
348 |
BDNF, Reduced |
leads to |
Aberrant, Dendritic morphology |
350 |
Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
leads to |
Tumorigenesis, Hepatocellular carcinoma |
351 |
Increased, Induced Mutations in Critical Genes |
leads to |
Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
352 |
Formation, Pro-mutagenic DNA Adducts |
leads to |
Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
353 |
BDNF, Reduced |
leads to |
Cell injury/death |
354 |
BDNF, Reduced |
leads to |
Reduced, Presynaptic release of glutamate |
355 |
Cell injury/death |
leads to |
Synaptogenesis, Decreased |
356 |
Aberrant, Dendritic morphology |
leads to |
Synaptogenesis, Decreased |
357 |
Reduced, Presynaptic release of glutamate |
leads to |
Synaptogenesis, Decreased |
358 |
Synaptogenesis, Decreased |
leads to |
Neuronal network function, Decreased |
359 |
Neuronal network function, Decreased |
leads to |
Impairment, Learning and memory |
360 |
Binding of agonist, NMDARs |
leads to |
Overactivation, NMDARs |
361 |
Overactivation, NMDARs |
leads to |
Increased, Intracellular Calcium overload |
362 |
Increased, Intracellular Calcium overload |
leads to |
N/A, Mitochondrial dysfunction 1 |
363 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Cell injury/death |
364 |
Cell injury/death |
leads to |
N/A, Neurodegeneration |
365 |
Cell injury/death |
leads to |
Neuroinflammation |
366 |
Thyroperoxidase, Inhibition |
leads to |
T4 in serum, Decreased |
368 |
N/A, Neurodegeneration |
leads to |
Neuronal network function, Decreased |
369 |
Activation, PPARα |
leads to |
Decrease, Steroidogenic acute regulatory protein (STAR) |
370 |
Activation, PPARα |
leads to |
Decrease, Translocator protein (TSPO) |
376 |
Covalent Binding, Protein |
leads to |
Response, Keratinocytes |
377 |
Covalent Binding, Protein |
leads to |
Activation, Dendritic Cells |
378 |
Response, Keratinocytes |
leads to |
Activation, Dendritic Cells |
379 |
Activation, Dendritic Cells |
leads to |
Activation/Proliferation, T-cells |
380 |
Response, Keratinocytes |
leads to |
Activation/Proliferation, T-cells |
383 |
Thyroperoxidase, Inhibition |
leads to |
Cognitive Function, Decreased |
384 |
Altered, Neurophysiology |
leads to |
Cognitive Function, Decreased |
385 |
Activation, Glucocorticoid Receptor |
leads to |
Induction, IKB inhibitory protein |
386 |
Induction, IKB inhibitory protein |
leads to |
Inhibition, Nuclear factor kappa B (NF-kB) |
387 |
Inhibition, Nuclear factor kappa B (NF-kB) |
leads to |
Suppression, Inflammatory cytokines |
388 |
Suppression, Inflammatory cytokines |
leads to |
Decreased, Lymphocytes |
389 |
Decreased, Lymphocytes |
leads to |
Increased, Disease susceptibility |
390 |
Decreased, Lymphocytes |
leads to |
Suppression, Immune system |
392 |
Reduction, Plasma 17beta-estradiol concentrations |
leads to |
irregularities, ovarian cycle |
393 |
irregularities, ovarian cycle |
leads to |
Decrease, Fertility |
394 |
irregularities, ovarian cycle |
leads to |
impaired, Fertility |
395 |
demethylation, PPARg promoter |
leads to |
reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
396 |
reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
398 |
Increase proliferation, Leydig cell |
leads to |
Hyperplasia, Leydig cell |
399 |
Decrease, Translocator protein (TSPO) |
leads to |
Reduction, Testosterone synthesis in Leydig cells |
402 |
Metabolism of AFB1, Production of Reactive Electrophiles |
leads to |
Formation, Pro-mutagenic DNA Adducts |
403 |
T4 in serum, Decreased |
leads to |
Cognitive Function, Decreased |
405 |
Malformation, Male reproductive tract |
leads to |
impaired, Fertility |
411 |
demethylation, PPARg promoter |
leads to |
Up Regulation, CD36 |
428 |
Increased Mortality |
leads to |
Decreased, Population trajectory |
432 |
Increased, Atrioventricular block and bradycardia |
leads to |
Increased Mortality |
433 |
Respiratory distress/arrest |
leads to |
Increased Mortality |
434 |
Increased Cholinergic Signaling |
leads to |
Increased Mortality |
436 |
Decrease, Steroidogenic acute regulatory protein (STAR) |
leads to |
Reduction, Cholesterol transport in mitochondria |
437 |
Decrease, Translocator protein (TSPO) |
leads to |
Reduction, Cholesterol transport in mitochondria |
438 |
Reduction, Cholesterol transport in mitochondria |
leads to |
Reduction, Testosterone synthesis in Leydig cells |
439 |
Reduction, Testosterone synthesis in Leydig cells |
leads to |
Reduction, testosterone level |
442 |
Inhibition, Na+/I- symporter (NIS) |
leads to |
Thyroidal Iodide, Decreased |
443 |
Thyroidal Iodide, Decreased |
leads to |
T4 in serum, Decreased |
444 |
T4 in neuronal tissue, Decreased |
leads to |
BDNF, Reduced |
445 |
BDNF, Reduced |
leads to |
Down Regulation, K-Cl co-transporter 2 (KCC2) |
446 |
Down Regulation, K-Cl co-transporter 2 (KCC2) |
leads to |
Delay, Developmental GABA shift |
447 |
Delay, Developmental GABA shift |
leads to |
Synaptogenesis, Decreased |
448 |
BDNF, Reduced |
leads to |
Synaptogenesis, Decreased |
449 |
AchE Inhibition |
leads to |
Increased, Atrioventricular block and bradycardia |
450 |
AchE Inhibition |
leads to |
Respiratory distress/arrest |
451 |
AchE Inhibition |
leads to |
Increased Cholinergic Signaling |
452 |
AchE Inhibition |
leads to |
Increased Mortality |
453 |
AchE Inhibition |
leads to |
Decreased, Population trajectory |
454 |
ACh Synaptic Accumulation |
leads to |
Increased, Atrioventricular block and bradycardia |
456 |
ACh Synaptic Accumulation |
leads to |
Increased Cholinergic Signaling |
457 |
Increased Cholinergic Signaling |
leads to |
Respiratory distress/arrest |
459 |
ACh Synaptic Accumulation |
leads to |
AchE Inhibition |
460 |
Reduction, testosterone level |
leads to |
Increase, Luteinizing hormone (LH) |
461 |
Increase, Luteinizing hormone (LH) |
leads to |
Increase proliferation, Leydig cell |
462 |
Hyperplasia, Leydig cell |
leads to |
impaired, Fertility |
470 |
Inhibition, Mitochondrial fatty acid beta-oxidation |
leads to |
Accumulation, Liver lipid |
471 |
Suppression, VLDL secretion |
leads to |
Accumulation, Liver lipid |
472 |
Accumulation, Fatty acid |
leads to |
Accumulation, Triglyceride |
473 |
Activation, AhR |
leads to |
Inhibition, Mitochondrial fatty acid beta-oxidation |
474 |
Accumulation, Triglyceride |
leads to |
Accumulation, Liver lipid |
475 |
Inhibition, Mitochondrial fatty acid beta-oxidation |
leads to |
Accumulation, Fatty acid |
476 |
Suppression, Constitutive androstane receptor, NR1l3 |
leads to |
Activation, LXR |
477 |
Suppression, Constitutive androstane receptor, NR1l3 |
leads to |
demethylation, PPARg promoter |
479 |
Activation, LXR |
leads to |
Activation, SREBF1 |
482 |
Activation, SREBF1 |
leads to |
Increased, De Novo FA synthesis |
483 |
Activation, ChREBP |
leads to |
Increased, De Novo FA synthesis |
484 |
Increased, De Novo FA synthesis |
leads to |
Increased, Triglyceride formation |
486 |
Increased, Triglyceride formation |
leads to |
Increased, Liver Steatosis |
487 |
demethylation, PPARg promoter |
leads to |
Activation, SREBF1 |
489 |
Activation, SREBF1 |
leads to |
Up Regulation, SCD-1 |
490 |
Activation, LXR |
leads to |
Up Regulation, FAS |
491 |
Activation, LXR |
leads to |
Up Regulation, SCD-1 |
492 |
Up Regulation, FAS |
leads to |
Increased, De Novo FA synthesis |
493 |
Up Regulation, SCD-1 |
leads to |
Increased, Triglyceride formation |
495 |
Activation, AhR |
leads to |
Up Regulation, CD36 |
496 |
Activation, AhR |
leads to |
Increased, FA Influx |
499 |
Activation, AhR |
leads to |
Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) |
501 |
Up Regulation, CD36 |
leads to |
Increased, FA Influx |
502 |
Accumulation, Fatty acid |
leads to |
Accumulation, Liver lipid |
503 |
Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) |
leads to |
Accumulation, Fatty acid |
504 |
Increased, FA Influx |
leads to |
Accumulation, Triglyceride |
505 |
Increased, FA Influx |
leads to |
Accumulation, Fatty acid |
506 |
Activation, AhR |
leads to |
Up Regulation, LDLR (low density lipoprotein receptor) |
507 |
Up Regulation, LDLR (low density lipoprotein receptor) |
leads to |
Increased, LDL uptake |
508 |
Increased, LDL uptake |
leads to |
Accumulation, Fatty acid |
509 |
Activation, AhR |
leads to |
Suppression, VLDL secretion |
510 |
Activation, LXR |
leads to |
Inhibition, PPAR alpha |
511 |
Inhibition, PPAR alpha |
leads to |
Inhibition, Mitochondrial fatty acid beta-oxidation |
512 |
Increased, De Novo FA synthesis |
leads to |
Accumulation, Fatty acid |
514 |
Accumulation, Fatty acid |
leads to |
Increased, Triglyceride formation |
515 |
Accumulation, Fatty acid |
leads to |
Increased, Liver Steatosis |
516 |
Activation, LXR |
leads to |
Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) |
517 |
Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) |
leads to |
Increased, De Novo FA synthesis |
518 |
Activation, PXR/SXR |
leads to |
Inhibition, FoxA2 |
519 |
Inhibition, FoxA2 |
leads to |
Down Regulation, CPT1A |
520 |
Down Regulation, CPT1A |
leads to |
Decreased, Mitochondrial fatty acid beta-oxidation |
523 |
Inhibition, FoxA2 |
leads to |
Down Regulation, HMGCS2 |
524 |
Down Regulation, HMGCS2 |
leads to |
Decreased, Ketogenesis |
526 |
Activation, PXR/SXR |
leads to |
Up Regulation, SCD-1 |
529 |
Activation, PXR/SXR |
leads to |
Up Regulation, CD36 |
532 |
Activation, NRF2 |
leads to |
Activation, NR1H4 |
533 |
Activation, NR1H4 |
leads to |
Activation, SHP |
534 |
Activation, NR1H4 |
leads to |
Activation, PPARα |
535 |
Activation, PPARα |
leads to |
Activation, LXR alpha |
537 |
Decreased, DHB4/HSD17B4 |
leads to |
Inhibition, Mitochondrial fatty acid beta-oxidation |
538 |
Inhibition, Mitochondrial fatty acid beta-oxidation |
leads to |
Increased, Liver Steatosis |
541 |
inflammation |
leads to |
Activation, AKT2 |
544 |
Decrease, Ovulation |
leads to |
Reduction, Cumulative fecundity and spawning |
547 |
Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts |
leads to |
Increased, Induced Mutations in Critical Genes |
548 |
Formation, Pro-mutagenic DNA Adducts |
leads to |
Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts |
549 |
Increased, Induced Mutations in Critical Genes |
leads to |
Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) |
550 |
Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) |
leads to |
Tumorigenesis, Hepatocellular carcinoma |
551 |
Formation, Pro-mutagenic DNA Adducts |
leads to |
Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) |
552 |
Inhibition, Na+/I- symporter (NIS) |
leads to |
TH synthesis, Decreased |
558 |
Reduced, Food storage |
leads to |
Decrease, Number of worker bees |
559 |
Decrease, Number of worker bees |
leads to |
Death/Failure, Colony |
562 |
Reduced, Food storage |
leads to |
impaired, Larval development |
563 |
impaired, Larval development |
leads to |
Death/Failure, Colony |
564 |
Impairment, Learning and memory |
leads to |
Abnormal, Roll change within caste |
565 |
Abnormal, Roll change within caste |
leads to |
Reduced, Brood care |
566 |
Reduced, Brood care |
leads to |
impaired, Larval development |
567 |
Increase, Energetic demands and therefore metabolic stress |
leads to |
Increased, Appetite and hunger |
568 |
Increased, Appetite and hunger |
leads to |
Abnormal, Foraging activity and behavior |
569 |
Abnormal, Foraging activity and behavior |
leads to |
Decrease, Number of worker bees |
570 |
Suppression, Immune system |
leads to |
Increased, Viral susceptibility |
571 |
Increased, Viral susceptibility |
leads to |
impaired, Development |
572 |
impaired, Development |
leads to |
Decrease, Number of worker bees |
573 |
Decrease, Number of worker bees |
leads to |
impaired, Hive thermoregulation |
574 |
impaired, Hive thermoregulation |
leads to |
Death/Failure, Colony |
575 |
Increased, Viral susceptibility |
leads to |
Abnormal, Foraging activity and behavior |
576 |
Decreased, Glucose oxidase enzyme activity |
leads to |
Decreased, Hydrogen peroxide production |
577 |
Decreased, Hydrogen peroxide production |
leads to |
Reduced, Antiseptic incorporated in food |
578 |
Reduced, Antiseptic incorporated in food |
leads to |
Abnormal, Roll change within caste |
579 |
Abnormal, Roll change within caste |
leads to |
Reduced, Food storage |
580 |
Abnormal, Roll change within caste |
leads to |
Decrease, Number of worker bees |
581 |
Activation, Nicotinic acetylcholine receptor |
leads to |
N/A, Mitochondrial dysfunction 1 |
582 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Neuronal network function, Decreased |
583 |
Impairment, Learning and memory |
leads to |
Abnormal, Foraging activity and behavior |
584 |
Abnormal, Foraging activity and behavior |
leads to |
Reduced, Food storage |
585 |
Inhibition, sodium channel |
leads to |
Decreased, Sodium conductance 1 |
586 |
Decreased, Sodium conductance 1 |
leads to |
Reduced, swimming speed |
587 |
Reduced, swimming speed |
leads to |
Reduced, feeding 1 |
588 |
Reduced, swimming speed |
leads to |
Increased, predation |
589 |
Reduced, feeding 1 |
leads to |
Increased, predation |
590 |
Inhibition, sodium channel |
leads to |
Increased, Atrioventricular block and bradycardia |
591 |
Increased, Atrioventricular block and bradycardia |
leads to |
Respiratory distress/arrest |
592 |
Respiratory distress/arrest |
leads to |
N/A, hypoxia |
593 |
N/A, hypoxia |
leads to |
Increased, amputations |
594 |
Decreased, Sodium conductance 1 |
leads to |
Increased, Atrioventricular block and bradycardia |
595 |
Increased, predation |
leads to |
Reduced, survival |
596 |
Reduced, feeding 1 |
leads to |
Reduced, survival |
597 |
Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel |
leads to |
Decreased, Sodium conductance 1 |
603 |
modulation, sodium channel |
leads to |
prolonged, Depolarization of neuronal membrane |
604 |
prolonged, Depolarization of neuronal membrane |
leads to |
Overactivation, Neuronotransmitter release |
605 |
Overactivation, Neuronotransmitter release |
leads to |
Overactivation, muscle contraction |
606 |
Overactivation, muscle contraction |
leads to |
Increased, Ataxia, paralysis, or hyperactivity |
607 |
Increased, Ataxia, paralysis, or hyperactivity |
leads to |
Increased Mortality |
608 |
Reduction, testosterone level |
leads to |
Malformation, Male reproductive tract |
617 |
Decreased, Mitochondrial fatty acid beta-oxidation |
leads to |
Increased, Liver Steatosis |
630 |
Occurrence, A paroxysmal depolarizing shift |
leads to |
Occurrence, Epileptic seizure |
634 |
Decreased, Neuronal network function in adult brain |
leads to |
Impairment, Learning and memory |
635 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
Increased, serotonin (5-HT) 1 |
636 |
Increased, serotonin (5-HT) 1 |
leads to |
Increase, cilia movement |
637 |
Increase, cilia movement |
leads to |
Increased, locomotion |
638 |
Increased, locomotion |
leads to |
Increase, predation |
639 |
Increase, cilia movement |
leads to |
Increased, foot detachment |
640 |
Increased, serotonin (5-HT) 1 |
leads to |
Increased, muscular waves in foot |
641 |
Increased, muscular waves in foot |
leads to |
Increased, locomotion |
642 |
Increased, muscular waves in foot |
leads to |
Increased, foot detachment |
643 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
Increased, serotonin (5-HT) |
644 |
Increased, serotonin (5-HT) |
leads to |
Decreased, anxiety |
645 |
Decreased, anxiety |
leads to |
Decreased, sheltering |
646 |
Decreased, sheltering |
leads to |
Increased, predation |
647 |
N/A, Neurodegeneration |
leads to |
Decreased, Neuronal network function in adult brain |
649 |
Decrease, histaminergic neuron excitation |
leads to |
N/A, sedation |
650 |
N/A, sedation |
leads to |
Decreased, locomotion |
651 |
Decreased, locomotion |
leads to |
Increased, predation |
654 |
Increased, predation |
leads to |
Decreased, survival |
656 |
Synaptogenesis, Decreased |
leads to |
Neuroinflammation |
658 |
Activation, Nicotinic acetylcholine receptor |
leads to |
Desensitization, Nicotinic acetylcholine receptor |
659 |
Desensitization, Nicotinic acetylcholine receptor |
leads to |
Neuronal network function, Decreased |
660 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Overwhelmed, Mitochondrial DNA repair mechanisms |
661 |
Overwhelmed, Mitochondrial DNA repair mechanisms |
leads to |
Accumulation, Damaged mitochondrial DNA |
662 |
Accumulation, Damaged mitochondrial DNA |
leads to |
Accelerated, Aging |
663 |
Accelerated, Aging |
leads to |
Decrease, Number of worker bees |
664 |
N/A, Mitochondrial dysfunction 1 |
leads to |
impaired, Thoracic shivering |
665 |
impaired, Thoracic shivering |
leads to |
impaired, Hive thermoregulation |
666 |
Binding at picrotoxin site, iGABAR chloride channel |
leads to |
Reduction, Ionotropic GABA receptor chloride channel conductance |
667 |
Reduction, Ionotropic GABA receptor chloride channel conductance |
leads to |
Reduction, Neuronal synaptic inhibition |
670 |
Inhibition, Cyclooxygenase activity |
leads to |
Reduced, Prostaglandin F2alpha synthesis, ovary |
671 |
Reduced, Prostaglandin F2alpha synthesis, ovary |
leads to |
Reduced, Prostaglandin F2alpha concentration, plasma |
672 |
Reduced, Prostaglandin F2alpha concentration, plasma |
leads to |
Reduced, Spawning behavior |
673 |
Reduced, Spawning behavior |
leads to |
Reduced, Ability to attract spawning mates |
674 |
Reduced, Ability to attract spawning mates |
leads to |
Reduced, Reproductive Success |
675 |
Reduced, Reproductive Success |
leads to |
Decrease, Population trajectory |
678 |
Reduced, Prostaglandin F2alpha concentration, plasma |
leads to |
Reduced, Pheromone release |
679 |
Reduced, Pheromone release |
leads to |
Reduced, Ability to attract spawning mates |
681 |
Inhibition, Cyclooxygenase activity |
leads to |
Decreased, Prostaglandin F2alpha synthesis, ovary |
682 |
Decreased, Prostaglandin F2alpha synthesis, ovary |
leads to |
Reduced, Prostaglandin F2alpha concentration, plasma |
683 |
Reduction, Neuronal synaptic inhibition |
leads to |
Generation, Amplified excitatory postsynaptic potential (EPSP) |
684 |
Generation, Amplified excitatory postsynaptic potential (EPSP) |
leads to |
Occurrence, A paroxysmal depolarizing shift |
685 |
Reduced, Prostaglandins, ovary |
leads to |
Decrease, Ovulation |
686 |
Inhibition, Cyclooxygenase activity |
leads to |
Reduced, Prostaglandins, ovary |
687 |
Decrease, Ovulation |
leads to |
Reduced, Reproductive Success |
689 |
Inhibition, Cyclooxygenase activity |
leads to |
Reduced, Prostaglandin E2 concentration, hypothalamus |
690 |
Reduced, Prostaglandin E2 concentration, hypothalamus |
leads to |
Reduced, Gonadotropin releasing hormone, hypothalamus |
691 |
Reduced, Gonadotropin releasing hormone, hypothalamus |
leads to |
Reduced, Luteinizing hormone (LH), plasma |
692 |
Reduced, Luteinizing hormone (LH), plasma |
leads to |
Reduced, Maturation inducing steroid, plasma |
693 |
Reduced, Maturation inducing steroid, plasma |
leads to |
Reduced, Maturation inducing steroid receptor signalling, oocyte |
694 |
Reduced, Maturation inducing steroid receptor signalling, oocyte |
leads to |
Increased, cyclic adenosine monophosphate |
695 |
Increased, cyclic adenosine monophosphate |
leads to |
Reduced, Reproductive Success |
696 |
Increased, cyclic adenosine monophosphate |
leads to |
Reduced, Meiotic prophase I/metaphase I transition, oocyte |
697 |
Reduced, Meiotic prophase I/metaphase I transition, oocyte |
leads to |
Reduced, Reproductive Success |
698 |
Reduced, Maturation inducing steroid receptor signalling, oocyte |
leads to |
Upregulated, Spindle assembly checkpoint protein Mad2-oocyte |
699 |
Upregulated, Spindle assembly checkpoint protein Mad2-oocyte |
leads to |
Increased, Chromosome misseggregation |
700 |
Increased, Chromosome misseggregation |
leads to |
Reduced, Reproductive Success |
701 |
impaired, ion channels |
leads to |
Altered, Action Potential |
702 |
Altered, Action Potential |
leads to |
Increased, cardiac arrthymia |
703 |
Increased, cardiac arrthymia |
leads to |
Increased Mortality |
706 |
Increased, Binding of chemicals to 2u (serum) |
leads to |
Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) |
707 |
Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) |
leads to |
Increase, Cytotoxicity (renal tubular cell) |
708 |
Increase, Cytotoxicity (renal tubular cell) |
leads to |
Increase, Regenerative cell proliferation (tubular epithelial cells) |
711 |
Activation, Constitutive androstane receptor |
leads to |
Increase, cell proliferation (hepatocytes) |
714 |
Binding, Tubulin |
leads to |
Disruption, Microtubule dynamics |
715 |
Disruption, Microtubule dynamics |
leads to |
Disorganization, Spindle |
716 |
Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme |
leads to |
Increased, Induction of pyruvate dehydrogenase (PDH) |
723 |
Altered, Chromosome number |
leads to |
Increase, Aneuploid offspring |
724 |
Binding, Tubulin |
leads to |
Altered, Chromosome number |
726 |
Increase, Necrosis (terminal bronchiolar cells) |
leads to |
Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
727 |
Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
leads to |
Increase, Hyperplasia (terminal bronchiolar cells) |
728 |
Increase, Hyperplasia (terminal bronchiolar cells) |
leads to |
Increase, Adenomas/carcinomas (bronchioloalveolar) |
729 |
Decreased, Androgen receptor activity |
leads to |
Decreased, Testosterone binding to androgen receptor (hypothalamus) |
730 |
Decreased, Testosterone binding to androgen receptor (hypothalamus) |
leads to |
Increase, Hyperplasia (Leydig cells) |
731 |
Increase, Hyperplasia (Leydig cells) |
leads to |
Increase, Leydig cell tumors |
732 |
Increase, Dopaminergic activity |
leads to |
Decreased, Prolactin |
733 |
Decreased, Prolactin |
leads to |
Increased, Estrogen receptor (ER) activity |
734 |
Increased, Estrogen receptor (ER) activity |
leads to |
Decreased, Progesterone from corpus luteum |
737 |
Disorganization, Spindle |
leads to |
Altered, Meiotic chromosome dynamics |
738 |
Altered, Meiotic chromosome dynamics |
leads to |
Altered, Chromosome number |
741 |
Increase, Thyroid-stimulating hormone (TSH) |
leads to |
Increase, Hypertrophy and proliferation (follicular cell) |
742 |
Increase, Hypertrophy and proliferation (follicular cell) |
leads to |
Increase, Hyperplasia (follicular cells) |
743 |
Increase, Hyperplasia (follicular cells) |
leads to |
Increase, Adenomas/carcinomas (follicular cell) |
744 |
Decreased, Testosterone binding to androgen receptor (hypothalamus) |
leads to |
Increased, Luteinizing hormone (LH) |
745 |
Increased, Luteinizing hormone (LH) |
leads to |
Increase, Hyperplasia (Leydig cells) |
746 |
T4 in neuronal tissue, Decreased |
leads to |
Hippocampal gene expression, Altered |
747 |
Hippocampal gene expression, Altered |
leads to |
Hippocampal anatomy, Altered |
748 |
Hippocampal Physiology, Altered |
leads to |
Cognitive Function, Decreased |
749 |
Hippocampal anatomy, Altered |
leads to |
Hippocampal Physiology, Altered |
750 |
Activation, 5HT2c |
leads to |
N/A, Unknown |
751 |
N/A, Unknown |
leads to |
Increased, Kidney Failure |
752 |
Activation, Glutamate-gated chloride channel |
leads to |
Increased, Chloride conductance |
755 |
hyperpolarisation, neuron |
leads to |
N/A, Ataxia, paralysis, or hyperactivity |
756 |
Increased Mortality |
leads to |
Decreased, population 1 |
757 |
N/A, Ataxia, paralysis, or hyperactivity |
leads to |
Increased Mortality |
758 |
Increased, Chloride conductance |
leads to |
hyperpolarisation, neuron |
759 |
Neuroinflammation |
leads to |
Synaptogenesis, Decreased |
760 |
Increase, Regenerative cell proliferation (tubular epithelial cells) |
leads to |
Increase, Hyperplasia (renal tubular cells) |
761 |
Increase, Hyperplasia (renal tubular cells) |
leads to |
Increase, Adenomas/carcinomas (renal tubular) |
762 |
Increased, Induction of pyruvate dehydrogenase (PDH) |
leads to |
Increase, Oxidative metabolism |
763 |
Increase, Oxidative metabolism |
leads to |
Peptide Oxidation |
764 |
Peptide Oxidation |
leads to |
Increase, hepatocellular adenomas and carcinomas |
765 |
Peptide Oxidation |
leads to |
Increase, Cytotoxicity |
766 |
Increase, Cytotoxicity |
leads to |
Increase, hepatocellular adenomas and carcinomas |
767 |
Increase, Cytotoxicity (club cells) |
leads to |
Increase, Necrosis (terminal bronchiolar cells) |
768 |
Decreased, Uptake of inorganic iodide |
leads to |
Decrease, Serum thyroid hormone (T4/T3) |
769 |
Decrease, Serum thyroid hormone (T4/T3) |
leads to |
Increase, Thyroid-stimulating hormone (TSH) |
770 |
Increase, Dopaminergic activity |
leads to |
Increase, Endometrial adenocarcinomas |
771 |
Increase, Hyperplasia (glandular epithelial cells of endometrium) |
leads to |
Increase, Endometrial adenocarcinomas |
772 |
Decreased, Progesterone from corpus luteum |
leads to |
Increase, Hyperplasia (glandular epithelial cells of endometrium) |
773 |
Increase, cell proliferation (hepatocytes) |
leads to |
Increase, Preneoplastic foci (hepatocytes) |
774 |
Increase, Preneoplastic foci (hepatocytes) |
leads to |
Increase, hepatocellular adenomas and carcinomas |
775 |
Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme |
leads to |
Increased, Plasma tyrosine |
776 |
Increased, Plasma tyrosine |
leads to |
Increase, Cytotoxicity (corneal cells) |
777 |
Increase, Cytotoxicity (corneal cells) |
leads to |
Increase, Inflammation (corneal cells) |
778 |
Increase, Inflammation (corneal cells) |
leads to |
Increase, Regenerative cell proliferation (corneal cells) |
779 |
Increase, Regenerative cell proliferation (corneal cells) |
leads to |
Increase, Papillomas/carcinomas (squamous cells) |
780 |
Increase, Cytotoxicity (epithelial cells) |
leads to |
Increase, Inflammation |
781 |
Increase, Inflammation |
leads to |
Increase, Regenerative cell proliferation (forestomach epithelial cells) |
782 |
Increase, Regenerative cell proliferation (forestomach epithelial cells) |
leads to |
Increase, Hyperplasia (forestomach epithelial cells) |
783 |
Increase, Hyperplasia (forestomach epithelial cells) |
leads to |
Increase, Papillomas/carcinomas (squamous cells) |
784 |
Increase, Cytotoxicity (tubular epithelial cells) |
leads to |
Increase, Regenerative cell proliferation (tubular epithelial cells) |
785 |
Increase, Regenerative cell proliferation (tubular epithelial cells) |
leads to |
Increase, Hyperplasia (tubular epithelial cells) |
786 |
Increase, Hyperplasia (tubular epithelial cells) |
leads to |
Increase, Adenomas/carcinomas (renal tubular) |
787 |
Activation, Androgen receptor |
leads to |
Increase, cell proliferation (hepatocytes) |
788 |
Increase, Cytotoxicity (hepatocytes) |
leads to |
Increase, Regenerative cell proliferation (hepatocytes) |
789 |
Increase, Regenerative cell proliferation (hepatocytes) |
leads to |
Increase, Preneoplastic foci (hepatocytes) |
790 |
Thyroperoxidase, Inhibition |
leads to |
Decrease, Incorporation of active iodide into iodotyrosines |
791 |
Decrease, Incorporation of active iodide into iodotyrosines |
leads to |
Decrease, Serum thyroid hormone (T4/T3) |
792 |
Inhibition, 5α-reductase activity |
leads to |
Decrease, Bioactivation of testosterone |
793 |
Decrease, Bioactivation of testosterone |
leads to |
Increased, Leutinizing hormone (LH) |
794 |
Increased, Leutinizing hormone (LH) |
leads to |
Increase, Hyperplasia (Leydig cells) |
795 |
Increase, Urinary bladder calculi |
leads to |
Increase, Cytotoxicity (urothelial cells) |
796 |
Increase, Cytotoxicity (urothelial cells) |
leads to |
Increase, Regenerative cell proliferation (urothelial cells) |
797 |
Increase, Regenerative cell proliferation (urothelial cells) |
leads to |
Increase, Hyperplasia (urothelial) |
798 |
Increase, Hyperplasia (urothelial) |
leads to |
Increase, Adenomas/carcinomas (urothelial) |
799 |
Inhibition, Prolyl hydroxylases |
leads to |
Increased, HIF-1 heterodimer |
800 |
Increased, HIF-1 heterodimer |
leads to |
Decreased, Aromatase (Cyp19a1) mRNA |
801 |
Decreased, Aromatase (Cyp19a1) mRNA |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
802 |
modulation, Unknown |
leads to |
Increased, HIF-1 alpha transcription |
803 |
Increased, HIF-1 alpha transcription |
leads to |
Increased, HIF-1 heterodimer |
804 |
Inhibition, HMG-CoA reductase |
leads to |
Decreased, mevalonate |
805 |
Decreased, mevalonate |
leads to |
Decreased, cholesterol |
806 |
Decreased, cholesterol |
leads to |
Decreased, Testosterone |
807 |
Decreased, Testosterone |
leads to |
malformed, Male reproductive tract |
808 |
malformed, Male reproductive tract |
leads to |
Decrease, Fertility |
809 |
TH synthesis, Decreased |
leads to |
Decreased, Thyroxine (T4) in serum |
810 |
TH synthesis, Decreased |
leads to |
Increased, Serum creatinine |
811 |
Decreased, Thyroxine (T4) in serum |
leads to |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
812 |
Decreased, Thyroxine (T4) in serum |
leads to |
Occurrence, Cystic dilatation (renal tubule) |
813 |
Increased, Serum creatinine |
leads to |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
814 |
Increased, Serum creatinine |
leads to |
Occurrence, Cystic dilatation (renal tubule) |
815 |
Decreased, Thyroxine (T4) in serum |
leads to |
Occurrence, Cytoplasmic vacuolization (podocyte) |
816 |
Increased, Serum creatinine |
leads to |
Occurrence, Cytoplasmic vacuolization (podocyte) |
817 |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
leads to |
Decreased, Glomerular filtration |
818 |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
leads to |
Decreased, Renal plasma flow |
819 |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
leads to |
Decreased, Sodium reabsorption |
820 |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
leads to |
Decreased, Renal ability to dilute urine |
821 |
Occurrence, Cystic dilatation (renal tubule) |
leads to |
Decreased, Glomerular filtration |
822 |
Occurrence, Cystic dilatation (renal tubule) |
leads to |
Decreased, Renal plasma flow |
823 |
Occurrence, Cystic dilatation (renal tubule) |
leads to |
Decreased, Sodium reabsorption |
824 |
Occurrence, Cystic dilatation (renal tubule) |
leads to |
Decreased, Renal ability to dilute urine |
825 |
Occurrence, Cytoplasmic vacuolization (podocyte) |
leads to |
Decreased, Glomerular filtration |
826 |
Occurrence, Cytoplasmic vacuolization (podocyte) |
leads to |
Decreased, Renal plasma flow |
827 |
Occurrence, Cytoplasmic vacuolization (podocyte) |
leads to |
Decreased, Sodium reabsorption |
828 |
Occurrence, Cytoplasmic vacuolization (podocyte) |
leads to |
Decreased, Renal ability to dilute urine |
829 |
Decreased, Glomerular filtration |
leads to |
Occurrence, Kidney toxicity |
830 |
Decreased, Renal plasma flow |
leads to |
Occurrence, Kidney toxicity |
831 |
Decreased, Sodium reabsorption |
leads to |
Occurrence, Kidney toxicity |
832 |
Decreased, Renal ability to dilute urine |
leads to |
Occurrence, Kidney toxicity |
833 |
Covalent Binding, Protein |
leads to |
Activation, Keratinocytes |
834 |
Activation, Keratinocytes |
leads to |
Activation, Dendritic Cells |
835 |
Activation/Proliferation, T-cells |
leads to |
sensitisation, skin |
836 |
Inhibition, Phospholipase A |
leads to |
Damage, Lipid bilayer |
837 |
Inhibition, Phospholipase A |
leads to |
Disturbance, Lysosomal function |
838 |
Inhibition, Phospholipase A |
leads to |
Injury, Mitochondria |
839 |
Damage, Lipid bilayer |
leads to |
Occurrence, Cytoplasmic vacuolization (hepatocyte) |
840 |
Damage, Lipid bilayer |
leads to |
Occurrence, Ballooning degeneration (hepatocyte) |
841 |
Damage, Lipid bilayer |
leads to |
Occurrence, Cytoplasmic vacuolization (Bile duct cell) |
842 |
Damage, Lipid bilayer |
leads to |
Occurrence, Cytoplasmic vacuolization (kupffer cell) |
843 |
Disturbance, Lysosomal function |
leads to |
Occurrence, Cytoplasmic vacuolization (hepatocyte) |
844 |
Disturbance, Lysosomal function |
leads to |
Occurrence, Ballooning degeneration (hepatocyte) |
845 |
Disturbance, Lysosomal function |
leads to |
Occurrence, Cytoplasmic vacuolization (Bile duct cell) |
846 |
Disturbance, Lysosomal function |
leads to |
Occurrence, Cytoplasmic vacuolization (kupffer cell) |
847 |
Injury, Mitochondria |
leads to |
Occurrence, Cytoplasmic vacuolization (hepatocyte) |
848 |
Injury, Mitochondria |
leads to |
Occurrence, Ballooning degeneration (hepatocyte) |
849 |
Injury, Mitochondria |
leads to |
Occurrence, Cytoplasmic vacuolization (Bile duct cell) |
850 |
Injury, Mitochondria |
leads to |
Occurrence, Cytoplasmic vacuolization (kupffer cell) |
851 |
Occurrence, Cytoplasmic vacuolization (hepatocyte) |
leads to |
Induction, Microvesicular fat |
852 |
Occurrence, Cytoplasmic vacuolization (hepatocyte) |
leads to |
Formation, Mallory body |
853 |
Occurrence, Ballooning degeneration (hepatocyte) |
leads to |
Induction, Microvesicular fat |
854 |
Occurrence, Ballooning degeneration (hepatocyte) |
leads to |
Formation, Mallory body |
855 |
Occurrence, Cytoplasmic vacuolization (Bile duct cell) |
leads to |
Induction, Microvesicular fat |
856 |
Occurrence, Cytoplasmic vacuolization (Bile duct cell) |
leads to |
Formation, Mallory body |
857 |
Occurrence, Cytoplasmic vacuolization (kupffer cell) |
leads to |
Induction, Microvesicular fat |
858 |
Occurrence, Cytoplasmic vacuolization (kupffer cell) |
leads to |
Formation, Mallory body |
859 |
Induction, Microvesicular fat |
leads to |
Formation, Liver fibrosis |
860 |
Formation, Mallory body |
leads to |
Formation, Liver fibrosis |
864 |
Oxidation, Uroporphyrinogen |
leads to |
Accumulation, Highly carboxylated porphyrins |
865 |
Oxidation, Uroporphyrinogen |
leads to |
Inhibition, UROD |
866 |
Accumulation, Highly carboxylated porphyrins |
leads to |
Uroporphyria |
867 |
Inhibition, UROD |
leads to |
Oxidation, Uroporphyrinogen |
868 |
Induction, CYP1A2/CYP1A5 |
leads to |
Oxidation, Uroporphyrinogen |
869 |
Activation, AhR |
leads to |
Induction, CYP1A2/CYP1A5 |
870 |
BDNF, Reduced |
leads to |
GABAergic interneurons, Decreased |
871 |
GABAergic interneurons, Decreased |
leads to |
Synaptogenesis, Decreased |
872 |
Thyroidal Iodide, Decreased |
leads to |
TH synthesis, Decreased |
874 |
Activation, Long term AHR receptor driven direct and indirect gene expression changes |
leads to |
Changes/Inhibition, Cellular Homeostasis and Apoptosis |
875 |
Activation, Long term AHR receptor driven direct and indirect gene expression changes |
leads to |
Alterations, Cellular proliferation / hyperplasia |
876 |
Activation, Long term AHR receptor driven direct and indirect gene expression changes |
leads to |
Formation, Hepatocellular and Bile duct tumors |
877 |
Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain |
leads to |
Decreased, PPARalpha transactivation of gene expression |
878 |
Decreased, PPARalpha transactivation of gene expression |
leads to |
Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
879 |
Decreased, PPARalpha transactivation of gene expression |
leads to |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
880 |
Decreased, PPARalpha transactivation of gene expression |
leads to |
Decreased, Ketogenesis (production of ketone bodies) |
881 |
Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
leads to |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
882 |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
leads to |
Decreased, Ketogenesis (production of ketone bodies) |
883 |
Decreased, Ketogenesis (production of ketone bodies) |
leads to |
Not Increased, Circulating Ketone Bodies |
884 |
Not Increased, Circulating Ketone Bodies |
leads to |
Increased, Catabolism of Muscle Protein |
885 |
Increased, Catabolism of Muscle Protein |
leads to |
Decreased, Body Weight |
886 |
Decrease, Intracellular pH |
leads to |
Increase, Cytotoxicity |
887 |
Increase, Cytotoxicity |
leads to |
Increase, Tissue Degeneration, Necrosis & Atrophy |
888 |
Increase, Tissue Degeneration, Necrosis & Atrophy |
leads to |
Increase, Respiratory or Squamous Metaplasia |
889 |
Increase, Respiratory or Squamous Metaplasia |
leads to |
Increase, Cell Proliferation |
890 |
Increase, Cell Proliferation |
leads to |
Increased, Induced Mutations in Critical Genes |
891 |
Increased, Induced Mutations in Critical Genes |
leads to |
Increase, Site of Contact Nasal Tumors |
892 |
Increased, Intracellular Calcium overload |
leads to |
Decreased, Neuronal network function in adult brain |
893 |
Increase, Cell Proliferation |
leads to |
Increase, Mutations in Critical Genes |
894 |
Increase, Mutations in Critical Genes |
leads to |
Increase, Site of Contact Nasal Tumors |
895 |
Increase, Cell Proliferation |
leads to |
Increase, Site of Contact Nasal Tumors |
896 |
Activation, SHP |
leads to |
Inhibition, SREBP1c |
899 |
Increase, Mutations |
leads to |
Increase, Cancer |
901 |
Alkylation, DNA |
leads to |
Increase, Cancer |
904 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Impaired, Proteostasis |
905 |
Impaired, Proteostasis |
leads to |
Degeneration of dopaminergic neurons of the nigrostriatal pathway |
906 |
Neuroinflammation |
leads to |
Degeneration of dopaminergic neurons of the nigrostriatal pathway |
907 |
Degeneration of dopaminergic neurons of the nigrostriatal pathway |
leads to |
Neuroinflammation |
908 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Degeneration of dopaminergic neurons of the nigrostriatal pathway |
910 |
Degeneration of dopaminergic neurons of the nigrostriatal pathway |
leads to |
Parkinsonian motor deficits |
911 |
Disruption, Lysosome |
leads to |
Increase, ROS production |
912 |
Increase, ROS production |
leads to |
N/A, Mitochondrial dysfunction 1 |
916 |
Infiltration, Inflammatory cells |
leads to |
Inflammation, Liver |
919 |
Binding of agonist, Ionotropic glutamate receptors |
leads to |
Overactivation, NMDARs |
921 |
Disruption, Lysosome |
leads to |
Peptide Oxidation |
922 |
Peptide Oxidation |
leads to |
N/A, Mitochondrial dysfunction 1 |
923 |
Peptide Oxidation |
leads to |
Release, Cytokine |
924 |
Cell injury/death |
leads to |
Release, Cytokine |
925 |
Release, Cytokine |
leads to |
Infiltration, Inflammatory cytokines |
926 |
Infiltration, Inflammatory cytokines |
leads to |
Inflammation, Liver |
927 |
Inhibition, Bile Salt Export Pump (ABCB11) |
leads to |
Bile accumulation, Pathological condition |
928 |
Bile accumulation, Pathological condition |
leads to |
Release, Cytokine |
929 |
Increase, Inflammation |
leads to |
Cholestasis, Pathology |
930 |
Bile accumulation, Pathological condition |
leads to |
Production, Reactive oxygen species |
931 |
Production, Reactive oxygen species |
leads to |
Cholestasis, Pathology |
932 |
Peptide Oxidation |
leads to |
Cholestasis, Pathology |
933 |
Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) |
leads to |
Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
934 |
Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
leads to |
N/A, Mitochondrial dysfunction 1 |
936 |
Activation, Epidermal Growth Factor Receptor |
leads to |
Decrease, Apoptosis of ciliated epithelial cells |
939 |
Activation, Epidermal Growth Factor Receptor |
leads to |
Increase, Proliferation of goblet cells |
942 |
Activation, Epidermal Growth Factor Receptor |
leads to |
Occurrence, Transdifferentiation of ciliated epithelial cells |
943 |
Occurrence, Transdifferentiation of ciliated epithelial cells |
leads to |
Occurrence, Metaplasia of goblet cells |
944 |
Increase, Proliferation of goblet cells |
leads to |
Goblet cell hyperplasia |
946 |
Activation, Epidermal Growth Factor Receptor |
leads to |
Activation, Sp1 |
948 |
Peptide Oxidation |
leads to |
Oxidation, Glutathione |
952 |
Decrease, GTPCH-1 |
leads to |
Decrease, Tetrahydrobiopterin |
953 |
Decrease, Tetrahydrobiopterin |
leads to |
Uncoupling, eNOS |
954 |
Oxidation, Glutathione |
leads to |
S-Glutathionylation, eNOS |
955 |
S-Glutathionylation, eNOS |
leads to |
Uncoupling, eNOS |
956 |
Uncoupling, eNOS |
leads to |
Depletion, Nitric Oxide |
958 |
Depletion, Nitric Oxide |
leads to |
Impaired, Vasodilation |
961 |
Decrease, Apoptosis of ciliated epithelial cells |
leads to |
Occurrence, Transdifferentiation of ciliated epithelial cells |
962 |
Activation, EGFR |
leads to |
Decrease, Apoptosis of ciliated epithelial cells |
964 |
Activation, EGFR |
leads to |
Activation, Sp1 |
965 |
Activation, EGFR |
leads to |
Occurrence, Transdifferentiation of ciliated epithelial cells |
970 |
Activation, EGFR |
leads to |
Increase, Proliferation of goblet cells |
972 |
Activation, AhR |
leads to |
dimerization, AHR/ARNT |
973 |
dimerization, AHR/ARNT |
leads to |
reduced dimerization, ARNT/HIF1-alpha |
974 |
reduced dimerization, ARNT/HIF1-alpha |
leads to |
reduced production, VEGF |
975 |
reduced production, VEGF |
leads to |
Impairment, Endothelial network |
976 |
Impairment, Endothelial network |
leads to |
Altered, Cardiovascular development/function |
977 |
Altered, Cardiovascular development/function |
leads to |
Increase, Pericardial edema |
980 |
Peptide Oxidation |
leads to |
Decrease, GTPCH-1 |
982 |
Impaired, Vasodilation |
leads to |
Increase, Vascular Resistance |
983 |
Increase, Vascular Resistance |
leads to |
Hypertension |
984 |
Activation, AhR |
leads to |
Increase, Early Life Stage Mortality |
986 |
Activation, EGFR |
leads to |
Increase, Mucin production |
987 |
Activation, Sp1 |
leads to |
Increase, Mucin production |
988 |
Decrease, AKT/eNOS activity |
leads to |
Depletion, Nitric Oxide |
989 |
Goblet cell hyperplasia |
leads to |
Hypersecretion, Mucus |
990 |
Occurrence, Metaplasia of goblet cells |
leads to |
Hypersecretion, Mucus |
991 |
Increase, Mucin production |
leads to |
Hypersecretion, Mucus |
992 |
Peptide Oxidation |
leads to |
Decrease, AKT/eNOS activity |
993 |
Disruption, Lysosome |
leads to |
N/A, Mitochondrial dysfunction 1 |
994 |
Release, Cytokine |
leads to |
Infiltration, Inflammatory cells |
995 |
Changes/Inhibition, Cellular Homeostasis and Apoptosis |
leads to |
N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
996 |
N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
leads to |
Alterations, Cellular proliferation / hyperplasia |
997 |
Alterations, Cellular proliferation / hyperplasia |
leads to |
Formation, Hepatocellular and Bile duct tumors |
998 |
Increase, EcR agonism |
leads to |
Decrease, Circulating ETH |
999 |
Increase, EcR agonism |
leads to |
Decreased, synthesis and secretion of molting fluid proteases |
1000 |
Decrease, Circulating ETH |
leads to |
Increase, Incomplete ecdysis |
1001 |
Decreased, synthesis and secretion of molting fluid proteases |
leads to |
Increase, Incomplete ecdysis |
1002 |
Increase, Incomplete ecdysis |
leads to |
Increase, Mortality |
1004 |
Increase, Mortality |
leads to |
Decreased, population 1 |
1007 |
Increase, EcR agonism |
leads to |
Decreased, Synthesis of molting fluid proteases |
1008 |
Decrease, Circulating ETH |
leads to |
Decrease, Abdominal muscle contraction |
1009 |
Decreased, Synthesis of molting fluid proteases |
leads to |
Decrease, Digestion of old cuticle |
1010 |
Decrease, Abdominal muscle contraction |
leads to |
Increase, Incomplete ecdysis |
1011 |
Decrease, Digestion of old cuticle |
leads to |
Increase, Incomplete ecdysis |
1013 |
Increase, Mortality |
leads to |
Decreased, Population size |
1015 |
Inhibition, Calcineurin Activity |
leads to |
Activation, Suppression of NFAT activation and hindrance of nuclear localization |
1016 |
Activation, Suppression of NFAT activation and hindrance of nuclear localization |
leads to |
Interference, nuclear localization of NFAT |
1017 |
Interference, nuclear localization of NFAT |
leads to |
Reduction, NFAT/AP-1 complex formation |
1018 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Suppression, Suppression in mixed lymphocyte reaction (MLR) |
1019 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Suppression, Suppression of T-cell dependent antibody response (TDAR) |
1020 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Impairment, T-cell dependent antibody response |
1021 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Relief, Relief of atopic dermatitis |
1022 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Increase, Increased susceptibility to infection |
1023 |
Binding of antagonist, PPAR alpha |
leads to |
stabilization, PPAR alpha co-repressor |
1024 |
stabilization, PPAR alpha co-repressor |
leads to |
Decreased, PPARalpha transactivation of gene expression |
1025 |
Abnormal, Morphogenesis |
leads to |
Increased, Developmental Defects |
1026 |
Inhibition, Deiodinase 2 |
leads to |
Decreased, Triiodothyronine (T3) in serum |
1027 |
Decreased, Triiodothyronine (T3) in serum |
leads to |
Reduced, Posterior swim bladder inflation |
1028 |
Reduced, Posterior swim bladder inflation |
leads to |
Reduced, Swimming performance |
1031 |
Reduced, Posterior swim bladder inflation |
leads to |
Reduced, Anterior swim bladder inflation |
1032 |
Reduced, Anterior swim bladder inflation |
leads to |
Reduced, Hearing |
1034 |
Reduced, Anterior swim bladder inflation |
leads to |
Reduced, Swimming performance |
1035 |
Decreased, Triiodothyronine (T3) in serum |
leads to |
Reduced, Anterior swim bladder inflation |
1036 |
Insufficiency, Vascular |
leads to |
Increased, Developmental Defects |
1037 |
Inhibition, Deiodinase 1 |
leads to |
Decreased, Triiodothyronine (T3) in serum |
1039 |
T4 in serum, Decreased |
leads to |
Reduced, Anterior swim bladder inflation |
1040 |
Thyroperoxidase, Inhibition |
leads to |
Reduced, Anterior swim bladder inflation |
1042 |
Inhibition, Deiodinase 2 |
leads to |
Reduced, Posterior swim bladder inflation |
1043 |
Inhibition, Deiodinase 2 |
leads to |
Reduced, Anterior swim bladder inflation |
1044 |
Inhibition, Deiodinase 1 |
leads to |
Reduced, Posterior swim bladder inflation |
1045 |
Inhibition, Deiodinase 1 |
leads to |
Reduced, Anterior swim bladder inflation |
1047 |
Increased, Chloride influx |
leads to |
Increased, Inhibitory postsynaptic potential |
1048 |
Increased, Inhibitory postsynaptic potential |
leads to |
Inhibition, Motor neuron activity |
1049 |
Inhibition, Motor neuron activity |
leads to |
Induction, Somatic muscle paralysis |
1050 |
Induction, Somatic muscle paralysis |
leads to |
Increased Mortality |
1051 |
Activation, ionotropic GABA Receptor chloride channel |
leads to |
Increased, Chloride conductance |
1052 |
Increased, Chloride conductance |
leads to |
Increased, Neuronal synaptic inhibition |
1053 |
Increased, Neuronal synaptic inhibition |
leads to |
Increased, Inhibitory postsynaptic potential |
1054 |
Increased, Inhibitory postsynaptic potential |
leads to |
Induction, Somatic muscle paralysis |
1055 |
Induction, Somatic muscle paralysis |
leads to |
Inhibition, Feeding |
1056 |
Inhibition, Feeding |
leads to |
Increased Mortality |
1057 |
Activation, Glutamate-gated chloride channels |
leads to |
Increased, Chloride conductance |
1058 |
Increased, Inhibitory postsynaptic potential |
leads to |
Induction, pharyngeal muscle paralysis |
1059 |
Induction, pharyngeal muscle paralysis |
leads to |
Inhibition, Feeding |
1061 |
Antagonism, Histamine Receptor (H2) |
leads to |
Decrease, histaminergic neuron excitation |
1062 |
Formation, The binding of FK506 with FKBP12 |
leads to |
Inhibition, Calcineurin Activity |
1063 |
Increased, induction of UDPGT's in liver |
leads to |
Increased, T4/T3 catabolism |
1064 |
Increased, T4/T3 catabolism |
leads to |
Decreased, serum T4/T3 |
1065 |
Decreased, serum T4/T3 |
leads to |
Increased, Thyroid-stimulating hormone (TSH) |
1066 |
Increased, Thyroid-stimulating hormone (TSH) |
leads to |
Increased, Hypertrophy and proliferation (follicular cell) |
1067 |
Increased, Hypertrophy and proliferation (follicular cell) |
leads to |
Increased, Hyperplasia (follicular cells) |
1068 |
Increased, Hyperplasia (follicular cells) |
leads to |
Increased Apoptosis, Adenomas/carcinomas (follicular cell) |
1069 |
N/A, Neurodegeneration |
leads to |
Impairment, Learning and memory |
1070 |
Inhibition, UROD |
leads to |
Accumulation, Highly carboxylated porphyrins |
1071 |
Activation of specific nuclear receptors, PPAR-gamma activation |
leads to |
Increased, adipogenesis |
1072 |
Activation of specific nuclear receptors, PPAR-gamma activation |
leads to |
Increased, secretion of local growth factors |
1073 |
Increased, adipogenesis |
leads to |
Increased, secretion of local growth factors |
1074 |
Increased, secretion of local growth factors |
leads to |
Increased, proliferation of mesenchymal cells |
1075 |
Increased, secretion of local growth factors |
leads to |
Increased, IGF-1 (mouse) |
1076 |
Increased, proliferation of mesenchymal cells |
leads to |
Increased, Firbrosarcoma |
1077 |
Increased, proliferation of mesenchymal cells |
leads to |
Increased, liposarcoma |
1078 |
Increased, proliferation of mesenchymal cells |
leads to |
Increased, hemagiosarcoma |
1079 |
Activation, beta-2 adrenergic receptor |
leads to |
Increased activity, beta-2 adrenergic receptor |
1080 |
Increased activity, beta-2 adrenergic receptor |
leads to |
relaxation, smooth muscle |
1081 |
relaxation, smooth muscle |
leads to |
Proliferation/Clonal Expansion, smooth muscle |
1082 |
Proliferation/Clonal Expansion, smooth muscle |
leads to |
Hypertrophy/hyperplasia, smooth muscle |
1083 |
Hypertrophy/hyperplasia, smooth muscle |
leads to |
Promotion, mesovarian leiomyomas |
1084 |
Decreased, Ovarian E2 |
leads to |
Increased, secretion of GnRH from hypothalamus |
1085 |
Decreased, Ovarian E2 |
leads to |
Decrease, E2 blood concentrations at hypothalamus |
1086 |
Suppression, Estrogen receptor (ER) activity |
leads to |
Decrease, E2 blood concentrations at hypothalamus |
1087 |
Decrease, E2 blood concentrations at hypothalamus |
leads to |
Increased, secretion of GnRH from hypothalamus |
1088 |
Increased, secretion of GnRH from hypothalamus |
leads to |
Increased, secrection of FSH from anterior pituitary |
1089 |
Increased, secretion of GnRH from hypothalamus |
leads to |
Increased, secretion of LH from anterior pituitary |
1090 |
Increased, secrection of FSH from anterior pituitary |
leads to |
Hyperplasia, ovarian stromal cells |
1091 |
Increased, secrection of FSH from anterior pituitary |
leads to |
Hyperplasia, ovarian epithelium |
1092 |
Increased, secretion of LH from anterior pituitary |
leads to |
Hyperplasia, ovarian stromal cells |
1093 |
Hyperplasia, ovarian epithelium |
leads to |
Promotion, ovarian adenomas |
1094 |
Hyperplasia, ovarian stromal cells |
leads to |
Promotion, ovarian granular cell tumors |
1095 |
Increased, PPAR-alpha activation |
leads to |
Decreased, bile flow |
1096 |
Increased, PPAR-alpha activation |
leads to |
Increased, cholestasis |
1097 |
Increased, PPAR-alpha activation |
leads to |
Alteration, lipid metabolism |
1098 |
prolonged, elevation of serun CCK |
leads to |
Increased, Cellular proliferation / hyperplasia of acinar cells |
1099 |
Increased, Cellular proliferation / hyperplasia of acinar cells |
leads to |
Increased, Pancreatic acinar tumors |
1100 |
Increased, cholestasis |
leads to |
prolonged, elevation of serun CCK |
1101 |
Decreased, bile flow |
leads to |
Increased, cholestasis |
1102 |
prepubertal increase, Estrogen receptor (ER) activity |
leads to |
Activation, estrogen receptor alpha |
1103 |
Activation, estrogen receptor alpha |
leads to |
Promotion, SIX-1 postive basal-type progenitor cells |
1104 |
Promotion, SIX-1 postive basal-type progenitor cells |
leads to |
Proliferation/Clonal Expansion, aberrant basal cells |
1105 |
Proliferation/Clonal Expansion, aberrant basal cells |
leads to |
squamous metaplasia, aberrant basal cells |
1106 |
squamous metaplasia, aberrant basal cells |
leads to |
Increased, Hyperplasia (glandular epithelial cells of endometrium) |
1107 |
Increased, Hyperplasia (glandular epithelial cells of endometrium) |
leads to |
Increased, adenosquamous carcinomas of endometrium |
1108 |
Decreased, GnRH pulsatility/release in hypothalamus |
leads to |
Decreased, LH Surge from anterior pituitary |
1109 |
Decreased, LH Surge from anterior pituitary |
leads to |
interruption, Ovulation |
1110 |
Decreased, LH Surge from anterior pituitary |
leads to |
prolonged, estrus |
1111 |
prolonged, estrus |
leads to |
Increased, circulating estrogen levels |
1112 |
prolonged, estrus |
leads to |
Increased, prolactin exposure |
1113 |
Increased, circulating estrogen levels |
leads to |
Hyperplasia, Mammary gland |
1114 |
Increased, prolactin exposure |
leads to |
Hyperplasia, Mammary gland |
1115 |
Hyperplasia, Mammary gland |
leads to |
Increased, latency period |
1116 |
Hyperplasia, Mammary gland |
leads to |
Increased, Adenomas/carcinomas (mammary) |
1117 |
Increased, latency period |
leads to |
Increased, Adenomas/carcinomas (mammary) |
1118 |
interruption, Ovulation |
leads to |
Increased, circulating estrogen levels |
1119 |
Increased, circulating estrogen levels |
leads to |
Increased, lactotroph hyperplasia and hypertrophy |
1120 |
Increased, lactotroph hyperplasia and hypertrophy |
leads to |
Increased, adenomas (pituitary) |
1121 |
Decreased, Dopaminergic activity |
leads to |
Increased, prolactin secretion |
1122 |
Increased, prolactin secretion |
leads to |
Increased, hyperplasia (mammary gland) |
1123 |
Increased, hyperplasia (mammary gland) |
leads to |
Increased, latency period |
1124 |
Increased, hyperplasia (mammary gland) |
leads to |
Increased, Adenomas/carcinomas (mammary) |
1125 |
persistent, cytotoxicity (pleura or peritoneum) |
leads to |
Increased, inflammation |
1126 |
persistent, cytotoxicity (pleura or peritoneum) |
leads to |
Increased, Oxidative Stress |
1127 |
Increased, inflammation |
leads to |
Increased, secretion of local growth factors |
1128 |
Increased, Oxidative Stress |
leads to |
Increased, secretion of local growth factors |
1129 |
Increased, secretion of local growth factors |
leads to |
Increased, Cell Proliferation (mesothelium) |
1130 |
Increased, Cell Proliferation (mesothelium) |
leads to |
Increased, mesotheliomas |
1131 |
Inhibition, organic anion transporter 1 (OAT1) |
leads to |
Increased, blood uric acid concentration |
1132 |
Increased, blood uric acid concentration |
leads to |
Occurrence, tophi (urate) deposition |
1133 |
Occurrence, tophi (urate) deposition |
leads to |
Occurrence, renal proximal tubular necrosis |
1134 |
Occurrence, renal proximal tubular necrosis |
leads to |
Increased, blood potassium concentration |
1135 |
Increased, blood potassium concentration |
leads to |
Occurrence, cardiac arrthymia |
1136 |
Occurrence, cardiac arrthymia |
leads to |
Increased Mortality |
1137 |
Inhibition, Cyclooxygenase 1 activity |
leads to |
Decreased, Prostaglandin F2alpha concentration, plasma |
1138 |
Decreased, Prostaglandin F2alpha concentration, plasma |
leads to |
Occurrence, renal ischemia |
1139 |
Occurrence, renal ischemia |
leads to |
Occurrence, renal proximal tubular necrosis |
1140 |
Increased, blood potassium concentration |
leads to |
Occurrence, cardiac arrhythmia |
1141 |
Occurrence, cardiac arrhythmia |
leads to |
Increased Mortality |
1142 |
Decreased, Thyroxine (T4) in tissues |
leads to |
Altered, Amphibian metamorphosis |
1143 |
T4 in serum, Decreased |
leads to |
Decreased, Thyroxine (T4) in tissues |
1144 |
Abnormal, Foraging activity and behavior |
leads to |
Weakened, Colony |
1145 |
Weakened, Colony |
leads to |
Death/Failure, Colony |
1146 |
Activation, Nicotinic acetylcholine receptor |
leads to |
Impairment, Learning and memory |
1147 |
Activation, Nicotinic acetylcholine receptor |
leads to |
Abnormal, Foraging activity and behavior |
1148 |
Abnormal, Foraging activity and behavior |
leads to |
Abnormal, Roll change within caste |
1149 |
Abnormal, Roll change within caste |
leads to |
Weakened, Colony |
1150 |
Abnormal, Foraging activity and behavior |
leads to |
Abnormal, Role change within caste |
1151 |
Abnormal, Role change within caste |
leads to |
Weakened, Colony |
1152 |
N/A, Mitochondrial dysfunction 1 |
leads to |
impaired, Hive thermoregulation |
1153 |
impaired, Hive thermoregulation |
leads to |
Weakened, Colony |
1154 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Weakened, Colony |
1155 |
Increased, Deformed Wing Virus levels |
leads to |
Weakened, Colony |
1156 |
Occurrence, renal proximal tubular necrosis |
leads to |
Increased, blood uric acid concentration |
1157 |
Increased, Energetic demands and therefore metabolic stress |
leads to |
Abnormal, Foraging activity and behavior |
1158 |
Increased, blood uric acid concentration |
leads to |
Increased, Oxidative Stress |
1159 |
Occurrence, renal ischemia |
leads to |
Increased, Oxidative Stress |
1160 |
Increased, Oxidative Stress |
leads to |
Occurrence, renal proximal tubular necrosis |
1161 |
Unknown, MIE |
leads to |
Increased, Reactive oxygen species |
1162 |
Increased, Reactive oxygen species |
leads to |
Increased, Oxidative Stress |
1163 |
Decreased, Thyroxine (T4) in tissues |
leads to |
Decreased, Triiodothyronine (T3) in tissues |
1164 |
Decreased, Triiodothyronine (T3) in tissues |
leads to |
Altered, Amphibian metamorphosis |
1165 |
Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo |
leads to |
Hemostasis, Depletion from blood of fully functional carboxylated clotting factors |
1166 |
Hemostasis, Depletion from blood of fully functional carboxylated clotting factors |
leads to |
Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur |
1167 |
Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle |
leads to |
Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo |
1168 |
Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur |
leads to |
Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) |
1169 |
Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) |
leads to |
Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis |
1170 |
Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis |
leads to |
Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction |
1171 |
Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction |
leads to |
Impaired recruitment , Population trajectory |
1172 |
Increased, serotonin (5-HT) 1 |
leads to |
Increased, valve movement |
1173 |
Increased, valve movement |
leads to |
Depletion, energy reserves |
1174 |
Increased, valve movement |
leads to |
Increased, water retention in foot |
1175 |
Increased, water retention in foot |
leads to |
Increased, foot detachment |
1176 |
Increased, foot detachment |
leads to |
Depletion, energy reserves |
1177 |
Increased, locomotion |
leads to |
Depletion, energy reserves |
1178 |
Increase, cilia movement |
leads to |
premature, spawning 1 |
1179 |
premature, spawning 1 |
leads to |
Decreased, Reproductive Success |
1180 |
Decreased, Reproductive Success |
leads to |
Decline, Population |
1181 |
Depletion, energy reserves |
leads to |
Delayed, Sexual maturity |
1182 |
Delayed, Sexual maturity |
leads to |
Decreased, Reproductive Success |
1183 |
Increased, foot detachment |
leads to |
Increase, predation |
1184 |
Increase, predation |
leads to |
Decline, Population |
1185 |
Depletion, energy reserves |
leads to |
Increase, predation |
1186 |
Increased, serotonin (5-HT) 1 |
leads to |
Decreased, gametogenesis |
1187 |
Increase, cilia movement |
leads to |
premature, Spawning |
1188 |
Decreased, gametogenesis |
leads to |
Decreased, Reproductive Success |
1189 |
Increased, serotonin (5-HT) 1 |
leads to |
Increased, locomotion |
1190 |
Increase, Incomplete ecdysis |
leads to |
Increased Mortality |
1191 |
Increased Mortality |
leads to |
Decreased, Population size |
1192 |
Increased, serotonin (5-HT) 1 |
leads to |
increased or inappropriate, mantel display |
1193 |
increased or inappropriate, mantel display |
leads to |
Decreased, Reproductive Success |
1194 |
Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p |
leads to |
Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei |
1195 |
Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei |
leads to |
Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp |
1196 |
Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp |
leads to |
Osteoporosis and vascular calcification, Bone deterioration |
1197 |
Inhibition, Iodotyrosine deiodinase (IYD) |
leads to |
Thyroidal Iodide, Decreased |
1198 |
Inhibition, Deiodinase 1 |
leads to |
Decreased, Triiodothyronine (T3) in tissues |
1199 |
Inhibition, Deiodinase 2 |
leads to |
Decreased, Triiodothyronine (T3) in tissues |
1200 |
Inhibition, Deiodinase 3 |
leads to |
Increased, Triiodothyronine (T3) in tissues |
1201 |
Increased, Triiodothyronine (T3) in tissues |
leads to |
Altered, Amphibian metamorphosis |
1202 |
Inhibition, Pendrin |
leads to |
TH synthesis, Decreased |
1203 |
Inhibition, Dual oxidase |
leads to |
TH synthesis, Decreased |
1204 |
Activation, Hepatic nuclear receptor(s) |
leads to |
Increased, Hepatic thyroid hormone uptake/transport |
1205 |
Activation, Hepatic nuclear receptor(s) |
leads to |
Induction, Upregulation of glucuronyltransferase activity |
1206 |
Increased, Hepatic thyroid hormone uptake/transport |
leads to |
Increase, Biliary excretion TH glucuronide |
1207 |
Increased, serotonin (5-HT) |
leads to |
Increased, mantel display |
1208 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
Increased, cilia movement |
1209 |
Increased, serotonin (5-HT) |
leads to |
Increased, cilia movement |
1210 |
Increased, cilia movement |
leads to |
premature, Spawning |
1211 |
premature, Spawning |
leads to |
Increased, Population |
1212 |
Increased, serotonin (5-HT) |
leads to |
Increased, oocyte maturation |
1213 |
Increased, oocyte maturation |
leads to |
Increased, Reproductive Success |
1214 |
Increased, mantel display |
leads to |
Increased, Reproductive Success |
1215 |
Increased, Reproductive Success |
leads to |
Increased, Population |
1216 |
Increased, valve movement |
leads to |
Increased, water pumping |
1217 |
Increase, cilia movement |
leads to |
Increased, water pumping |
1218 |
Increase, cilia movement |
leads to |
Depletion, energy reserves |
1219 |
increased or inappropriate, mantel display |
leads to |
Depletion, energy reserves |
1220 |
increased or inappropriate, mantel display |
leads to |
induced, parturition |
1221 |
induced, parturition |
leads to |
Decreased, Reproductive Success |
1222 |
premature, Spawning |
leads to |
Decreased, Reproductive Success |
1223 |
Increased, water retention in foot |
leads to |
Increased, valve movement |
1224 |
Increased, water pumping |
leads to |
Increased, water retention in foot |
1225 |
Increased, water pumping |
leads to |
premature, Spawning |
1226 |
Increased, water pumping |
leads to |
induced, parturition |
1227 |
Increased, valve movement |
leads to |
Increase, predation |
1228 |
Increased, muscular waves in foot |
leads to |
Depletion, energy reserves |
1229 |
Activation, PPARα |
leads to |
Increase, Phenotypic enzyme activity |
1230 |
Increase, Phenotypic enzyme activity |
leads to |
Increase, cell proliferation (hepatocytes) |
1231 |
Increase, Phenotypic enzyme activity |
leads to |
Increase, Clonal Expansion of Altered Hepatic Foci |
1232 |
Increase, Clonal Expansion of Altered Hepatic Foci |
leads to |
Increase, hepatocellular adenomas and carcinomas |
1233 |
Activation, PPARα |
leads to |
Increase, Genes involved in fatty acid oxidation |
1234 |
Increase, Genes involved in fatty acid oxidation |
leads to |
Peptide Oxidation |
1235 |
Activation, NADPH Oxidase |
leads to |
Peptide Oxidation |
1236 |
Activation, PPARα |
leads to |
Activation, NADPH Oxidase |
1237 |
Peptide Oxidation |
leads to |
Increase activation, Nuclear factor kappa B (NF-kB) |
1238 |
Increase activation, Nuclear factor kappa B (NF-kB) |
leads to |
Increase, Phenotypic enzyme activity |
1239 |
Increase, cell proliferation (hepatocytes) |
leads to |
Increase, Clonal Expansion of Altered Hepatic Foci |
1240 |
Increase, Genes involved in fatty acid oxidation |
leads to |
Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
1241 |
Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
leads to |
Peptide Oxidation |
1242 |
Inhibition, sodium channel |
leads to |
Decreased, sodium conductance 2 |
1243 |
Decreased, sodium conductance 2 |
leads to |
Decreased, Ionotropic GABA receptor chloride channel conductance |
1244 |
Decreased, sodium conductance 2 |
leads to |
Decreased, GABA release |
1245 |
Decreased, GABA release |
leads to |
Decreased, Chloride conductance |
1246 |
Activation, Estrogen receptor |
leads to |
Increased, ER binding to DNA (classical pathway) |
1247 |
Increase, Cell Proliferation (Epithelial Cells) |
leads to |
Increased, Ductal Hyperplasia |
1248 |
Decreased, Apoptosis (Epithelial Cells) |
leads to |
Increased, Ductal Hyperplasia |
1249 |
Activation, Estrogen receptor |
leads to |
Increased, ER binding to T.F. to DNA (non-classical pathway) |
1250 |
Increased, ER binding to DNA (classical pathway) |
leads to |
Increase, Cell Proliferation (Epithelial Cells) |
1251 |
Increased, ER binding to T.F. to DNA (non-classical pathway) |
leads to |
Increase, Cell Proliferation (Epithelial Cells) |
1252 |
Increased, Ductal Hyperplasia |
leads to |
N/A, Breast Cancer |
1253 |
Binding, Immunophilins |
leads to |
Inhibition, Calcineurin Activity |
1254 |
Inhibition, Calcineurin Activity |
leads to |
Suppression, IL-2 and IL-4 production |
1255 |
Suppression, IL-2 and IL-4 production |
leads to |
Interference, nuclear localization of NFAT |
1256 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Suppression, Suppression of production of cytotoxic T-cells |
1257 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Suppression, Suppression of T-cell dependent antibody production |
1258 |
Suppression, Suppression of production of cytotoxic T-cells |
leads to |
Impairment, T-cell dependent antibody response |
1259 |
Suppression, Suppression of T-cell dependent antibody production |
leads to |
Increase, Increased susceptibility to infection |
1260 |
Suppression, Suppression of production of cytotoxic T-cells |
leads to |
Increase, Increased susceptibility to infection |
1261 |
Activation, Juvenile hormone receptor |
leads to |
Induction, Doublesex1 gene |
1262 |
Induction, Doublesex1 gene |
leads to |
Induction, Male reproductive tract |
1263 |
Induction, Male reproductive tract |
leads to |
Increased, Male offspring |
1264 |
Increased, Male offspring |
leads to |
Decline, Population |
1265 |
Decline, Population |
leads to |
Alteration, Food-web structures |
1266 |
Increased, Proliferation (Endothelial cells) |
leads to |
Increased, Angiogenesis |
1267 |
Increased, Migration (Endothelial Cells) |
leads to |
Increased, Angiogenesis |
1268 |
Activation, Constitutive androstane receptor |
leads to |
Altered expression of hepatic CAR-dependent genes |
1269 |
Altered expression of hepatic CAR-dependent genes |
leads to |
Increase, cell proliferation (hepatocytes) |
1271 |
TRPA1 activation, TRPA1 Receptor |
leads to |
Opening of calcium channel, Calcium influx |
1272 |
Opening of calcium channel, Calcium influx |
leads to |
Sensory Airway Irritation |
1273 |
Sensory Airway Irritation |
leads to |
Cough, Dyspnea, Sneezing, Acute respiratory effect |
1274 |
Opening of calcium channel, Calcium influx |
leads to |
Excitation, Trigeminal nerve excitation |
1275 |
Excitation, Trigeminal nerve excitation |
leads to |
Cough, Dyspnea, Sneezing, Acute respiratory effect |
1276 |
Excitation, Trigeminal nerve excitation |
leads to |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
1277 |
Non-neuronal production of TNF, Epithelial irritation |
leads to |
Leukocyte infiltration |
1278 |
Leukocyte infiltration |
leads to |
Respiratory irritability |
1279 |
SP (Substance P) release, Local increase of SP |
leads to |
Non-neuronal production of TNF, Epithelial irritation |
1280 |
Opening of calcium channel, Calcium influx |
leads to |
SP (Substance P) release, Local increase of SP |
1281 |
TRPV1 activation, TRPV1 |
leads to |
Opening of calcium channel, Calcium influx |
1282 |
Oxidization of biomolecules, Lipid bilayer and cellular proteins |
leads to |
TRPA1 activation, TRPA1 Receptor |
1283 |
Production of nerve growth factor , Epithelial irritation |
leads to |
SP (Substance P) release, Local increase of SP |
1284 |
TRPA1 activation, TRPA1 Receptor |
leads to |
Non-neuronal production of IL-8/CXCL1, Epithelial irritation |
1285 |
Oxidization of biomolecules, Lipid bilayer and cellular proteins |
leads to |
Generation of novel epitopes , Antigen presentation |
1286 |
Oxidization of biomolecules, Lipid bilayer and cellular proteins |
leads to |
Production of nerve growth factor , Epithelial irritation |
1287 |
Non-neuronal production of IL-8/CXCL1, Epithelial irritation |
leads to |
Opening of calcium channel, Calcium influx |
1288 |
Non-neuronal production of TNF, Epithelial irritation |
leads to |
Opening of calcium channel, Calcium influx |
1289 |
Generation of novel epitopes , Antigen presentation |
leads to |
Sensitization, Immune system |
1290 |
Leukocyte infiltration |
leads to |
Sensitization, Immune system |
1291 |
Oxidation |
leads to |
Generation of novel epitopes , Antigen presentation |
1292 |
Oxidation |
leads to |
TRPA1 activation, TRPA1 Receptor |
1293 |
Oxidation |
leads to |
Production of nerve growth factor , Epithelial irritation |
1294 |
Activation, Estrogen receptor |
leads to |
Increased, Non-genomic signaling |
1295 |
Increased, Non-genomic signaling |
leads to |
Increased, ER binding to T.F. to DNA (non-classical pathway) |
1296 |
Increased, ER binding to DNA (classical pathway) |
leads to |
Altered, Gene Expression |
1297 |
Increased, ER binding to T.F. to DNA (non-classical pathway) |
leads to |
Altered, Gene Expression |
1298 |
Altered, Gene Expression |
leads to |
Altered, Protein Production |
1299 |
Altered, Protein Production |
leads to |
Increased, Oxidative Stress |
1300 |
Increased, Oxidative Stress |
leads to |
Increase, DNA Damage |
1301 |
Increase, DNA Damage |
leads to |
Altered, Gene Expression |
1302 |
Increased, Non-genomic signaling |
leads to |
Altered, Gene Expression |
1303 |
Altered, Protein Production |
leads to |
Increased, Proliferation (Endothelial cells) |
1304 |
Altered, Protein Production |
leads to |
Decreased, Apoptosis (Epithelial Cells) |
1305 |
Altered, Protein Production |
leads to |
Increased, Motility |
1306 |
Increased, Motility |
leads to |
Increased, Invasion |
1307 |
Activation, Estrogen receptor |
leads to |
Increased, Second Messenger Production |
1308 |
Increased, Second Messenger Production |
leads to |
Increased, Non-genomic signaling |
1309 |
Desensitization, Nicotinic acetylcholine receptor |
leads to |
Altered, Ca2+-calmodulin activated signal transduction |
1310 |
Altered, Ca2+-calmodulin activated signal transduction |
leads to |
Impairment, Learning and memory |
1311 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Altered, Ca2+-calmodulin activated signal transduction |
1312 |
Goblet cell hyperplasia |
leads to |
Increase, Mucin production |
1313 |
Occurrence, Metaplasia of goblet cells |
leads to |
Increase, Mucin production |
1314 |
Chronic, Mucus hypersecretion |
leads to |
Decrease, Lung function |
1315 |
Increase, Mucin production |
leads to |
Chronic, Mucus hypersecretion |
1316 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
Increased, muscular waves in foot |
1317 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
Increased, valve movement |
1318 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
Increase, cilia movement |
1319 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
increased mantel display |
1320 |
Increased, valve movement |
leads to |
induced spawning |
1321 |
Increase, cilia movement |
leads to |
induced spawning |
1322 |
increased mantel display |
leads to |
Induced parturition |
1323 |
Induced parturition |
leads to |
Decreased, Reproductive Success |
1324 |
induced spawning |
leads to |
Decreased, Reproductive Success |
1325 |
induced spawning |
leads to |
Increased, Reproductive Success |
1326 |
Induced parturition |
leads to |
Increased, Reproductive Success |
1327 |
Increased, serotonin (5-HT) |
leads to |
Increased, valve movement |
1328 |
Increased, oocyte maturation |
leads to |
induced spawning |
1329 |
Increased, cilia movement |
leads to |
induced spawning |
1330 |
Binding, topoisomerase II |
leads to |
MLL translocation |
1331 |
MLL translocation |
leads to |
IFL |
1332 |
Increased, serotonin (5-HT) |
leads to |
Increased, muscular waves in foot |
1333 |
Increased, serotonin (5-HT) |
leads to |
Increase, cilia movement |
1334 |
Increased, valve movement |
leads to |
Induced parturition |
1335 |
Increase, cilia movement |
leads to |
Induced parturition |
1336 |
Increased, serotonin (5-HT) |
leads to |
increased mantel display |
1337 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
leads to |
Increased, oocyte maturation |
1338 |
Decompartmentalization |
leads to |
Mitochondrial impairment |
1339 |
Direct mitochondrial inhibition |
leads to |
Mitochondrial impairment |
1340 |
narcosis |
leads to |
Mitochondrial impairment |
1341 |
Mitochondrial impairment |
leads to |
Apoptosis |
1342 |
Mitochondrial impairment |
leads to |
Necrosis |
1343 |
Increase, EcR agonism |
leads to |
Increase, E75b expression |
1344 |
Increase, E75b expression |
leads to |
Increase, Ftz-f1 expression |
1345 |
Increase, Ftz-f1 expression |
leads to |
Decrease, Circulating ETH |
1346 |
Decrease, Circulating ETH |
leads to |
Decrease, Circulating CCAP |
1347 |
Decrease, Circulating CCAP |
leads to |
Decrease, Ecdysis motoneuron bursts |
1348 |
Decrease, Ecdysis motoneuron bursts |
leads to |
Decrease, Excitatory postsynaptic potential |
1349 |
Decrease, Excitatory postsynaptic potential |
leads to |
Decrease, Abdominal muscle contraction |
1350 |
dimerization, AHR/ARNT |
leads to |
Increase, COX-2 expression |
1351 |
Increase, COX-2 expression |
leads to |
Altered, Cardiovascular development/function |
1352 |
Altered, Cardiovascular development/function |
leads to |
Increase, Mortality |
1353 |
Inactivation of PPARγ |
leads to |
Activation of TGF-β signaling |
1354 |
Activation of TGF-β signaling |
leads to |
Differentiation of Myofibroblast |
1355 |
Activation of TGF-β signaling |
leads to |
Expression of Collagen |
1356 |
Differentiation of Myofibroblast |
leads to |
Production of α-smooth muscle actin |
1357 |
Expression of Collagen |
leads to |
Collagen Deposition |
1358 |
Production of α-smooth muscle actin |
leads to |
Lung fibrosis |
1359 |
Collagen Deposition |
leads to |
Lung fibrosis |
1360 |
Activation, NADPH Oxidase |
leads to |
ROS formation |
1361 |
ROS formation |
leads to |
Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK |
1362 |
Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK |
leads to |
Increased, DNA Damage-Repair |
1363 |
Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK |
leads to |
Damaging, Mitochondria |
1364 |
Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK |
leads to |
Activation, HIF-1 |
1365 |
Activation, HIF-1 |
leads to |
Apoptosis |
1366 |
Increased, DNA Damage-Repair |
leads to |
Apoptosis |
1367 |
Damaging, Mitochondria |
leads to |
Apoptosis |
1368 |
Apoptosis |
leads to |
Reproductive failure |
1369 |
Activation, JAK/STAT pathway |
leads to |
Activation, TGF-beta pathway |
1370 |
Activation, TGF-beta pathway |
leads to |
Reproductive failure |
1371 |
Up Regulation, SREBF2 |
leads to |
Up Regulation, Unsaturated fatty acid |
1372 |
Up Regulation, Unsaturated fatty acid |
leads to |
Perturbation of cholesterol |
1373 |
Down Regulation, GSS and GSTs gene |
leads to |
Glutathione synthesis |
1374 |
Glutathione synthesis |
leads to |
Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene |
1375 |
Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene |
leads to |
Perturbation of cholesterol |
1376 |
Down Regulation, GSS and GSTs gene |
leads to |
Glutathione homeostasis |
1377 |
Perturbation of cholesterol |
leads to |
Hepatotoxicity |
1378 |
Glutathione homeostasis |
leads to |
Hepatotoxicity |
1379 |
Peptide Oxidation |
leads to |
Activation, JNK |
1380 |
Activation, JNK |
leads to |
Activation, FOXO |
1381 |
Activation, FOXO |
leads to |
Inhibition, Wnt pathway |
1382 |
Inhibition, Wnt pathway |
leads to |
Defect of Embryogenesis |
1383 |
Defect of Embryogenesis |
leads to |
Reproductive failure |
1384 |
Agonism, Androgen receptor |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
1385 |
Agonism, Androgen receptor |
leads to |
Reduction, Vitellogenin synthesis in liver |
1386 |
Reduction, Plasma 17beta-estradiol concentrations |
leads to |
Reduction, Plasma vitellogenin concentrations |
1387 |
T4 in serum, Decreased |
leads to |
Hippocampal gene expression, Altered |
1388 |
T4 in serum, Decreased |
leads to |
Hippocampal anatomy, Altered |
1389 |
T4 in serum, Decreased |
leads to |
Hippocampal Physiology, Altered |
1390 |
Increase, insulin |
leads to |
Activation, insulin receptor |
1391 |
Activation, insulin receptor |
leads to |
Activation, mTORC2 |
1392 |
Activation, mTORC2 |
leads to |
Activation, AKT |
1393 |
Activation, mTORC2 |
leads to |
Activation, mTORC1 |
1394 |
Activation, AKT |
leads to |
Activation, SREBP-1 |
1395 |
Activation, mTORC1 |
leads to |
Activation, L-FABP |
1396 |
Activation, mTORC1 |
leads to |
Activation, HSD17B4 |
1397 |
Activation, SREBP-1 |
leads to |
Activation, FXR |
1398 |
Activation, AKT |
leads to |
Activation, mTORC1 |
1399 |
Activation, mTORC1 |
leads to |
Activation, SREBP-1 |
1400 |
Activation, AKT |
leads to |
Activation, L-FABP |
1401 |
Activation, L-FABP |
leads to |
Increase, cytosolic fatty acid |
1402 |
demethylation, PPARg promoter |
leads to |
Activation, SREBP-1 |
1403 |
Activation, SREBP-1 |
leads to |
Activation, SCD-1 |
1404 |
Activation, SCD-1 |
leads to |
Increased, lipogenesis |
1405 |
Increased, lipogenesis |
leads to |
Increase, cytosolic fatty acid |
1406 |
Activation, NRF2 |
leads to |
Activation, FXR |
1407 |
Activation, FXR |
leads to |
Activation, SHP |
1408 |
Activation, FXR |
leads to |
Activation, PPARα |
1409 |
Activation, SHP |
leads to |
Activation, PPARα |
1410 |
Activation, PPARα |
leads to |
Activation, HSD17B4 |
1411 |
Activation, HSD17B4 |
leads to |
Inhibition, Mitochondrial fatty acid beta-oxidation |
1412 |
Activation, SHP |
leads to |
Inhibition, LXR |
1413 |
Inhibition, LXR |
leads to |
Inhibition, PPAR alpha |
1414 |
Activation, SHP |
leads to |
Inhibition, LRH-1 |
1415 |
Activation, HSD17B4 |
leads to |
Increase, Fatty acid β-oxidation |
1416 |
Increase, Fatty acid β-oxidation |
leads to |
Inhibition, Steatosis |
1417 |
Increase, Fatty acid β-oxidation |
leads to |
Decrease, cytosolic fatty acid |
1418 |
Activation, PI3K |
leads to |
Activation, AKT |
1419 |
Activation, PI3K |
leads to |
Activation, L-FABP |
1420 |
Activation, PI3K |
leads to |
Activation, aPKC |
1421 |
Activation, aPKC |
leads to |
Activation, SREBP-1 |
1422 |
Activation, FAS |
leads to |
Increased, lipogenesis |
1423 |
Activation, L-FABP |
leads to |
demethylation, PPARg promoter |
1424 |
demethylation, PPARg promoter |
leads to |
Activation, FAS |
1425 |
Activation, LRH-1 |
leads to |
Activation, FAS |
1426 |
Decreased, serotonin transporter activity |
leads to |
Increased, intracellular sodium (Na+) |
1427 |
Decreased, serotonin transporter activity |
leads to |
Increased, intracellular chloride (Cl-) |
1428 |
Decreased, serotonin transporter activity |
leads to |
Decreased, extracellular Na+ |
1429 |
Decreased, serotonin transporter activity |
leads to |
Decreased, extracellular chloride (Cl-) |
1430 |
Decreased, serotonin transporter activity |
leads to |
Increased, extracellular serotonin |
1431 |
Decreased, serotonin transporter activity |
leads to |
Decreased, intracellular serotonin |
1432 |
Decreased, intracellular serotonin |
leads to |
Decreased, packaged serotonin |
1433 |
Decreased, packaged serotonin |
leads to |
Decreased, synaptic release |
1434 |
Decreased, synaptic release |
leads to |
Decreased, extracellular serotonin |
1435 |
Decreased, extracellular serotonin |
leads to |
Increased, 5-HT3 |
1436 |
Decreased, extracellular serotonin |
leads to |
Inactivated, 5-HTR |
1437 |
Decreased, extracellular serotonin |
leads to |
Activation, 5-HT2A |
1438 |
Activation, 5-HT2A |
leads to |
Activate, PLC |
1439 |
Activate, PLC |
leads to |
Increase, inositol triphosphate |
1440 |
Increase, inositol triphosphate |
leads to |
Increase, intracellular calcium |
1441 |
Increase, intracellular calcium |
leads to |
Activate, calmodulin |
1442 |
Activate, calmodulin |
leads to |
Increase, myosin light chain phosphorylation |
1443 |
Increase, myosin light chain phosphorylation |
leads to |
Increase, vascular smooth muscle contraction |
1444 |
Increase, vascular smooth muscle contraction |
leads to |
Increase, hypertension |
1445 |
Increased, 5-HT3 |
leads to |
Increased, seizure |
1446 |
Inactivated, 5-HTR |
leads to |
Reduce expression, BDNF |
1447 |
Reduce expression, BDNF |
leads to |
Decreased, neuroplasticity |
1448 |
Decreased, neuroplasticity |
leads to |
Increased, agitation |
1449 |
Decreased, neuroplasticity |
leads to |
Increased, depression |
1450 |
Increase, cortisone |
leads to |
Activation, Glucocorticoid Receptor |
1451 |
Activation, Glucocorticoid Receptor |
leads to |
Reduced, BDNF |
1452 |
Activated, presynaptic neuron 1 |
leads to |
Increased, glutamate |
1453 |
Increased, glutamate |
leads to |
Activated, NMDA receptor |
1454 |
Activated, NMDA receptor |
leads to |
Increased, intracellular sodium (Na+) |
1455 |
Increased, intracellular sodium (Na+) |
leads to |
Activated, voltage-gated sodium channel |
1456 |
Treat, carbamazepine |
leads to |
Inhibit, voltage-gated sodium channel |
1457 |
Activated, voltage-gated sodium channel |
leads to |
Activated, membrane depolarization |
1458 |
Activated, membrane depolarization |
leads to |
Increased, hippocampal hyperdepolarization |
1459 |
Increased, hippocampal hyperdepolarization |
leads to |
Increase, seizure |
1460 |
Increase, seizure |
leads to |
Increased, epilepsy |
1461 |
Activate, presynaptic neuron 2 |
leads to |
Increase, GABA |
1462 |
Increase, GABA |
leads to |
Activate, GABA-A receptor |
1463 |
Increased, RDX dose |
leads to |
Activate, GABA-A receptor |
1464 |
Activate, GABA-A receptor |
leads to |
Increased, intracellular chloride (Cl-) |
1465 |
Increased, intracellular chloride (Cl-) |
leads to |
Inactive, membrane depolarization |
1466 |
Increase, ROS |
leads to |
Peptide Oxidation |
1467 |
Peptide Oxidation |
leads to |
Increase, DNA Damage |
1468 |
Increase, DNA Damage |
leads to |
Increase, Apoptosis |
1469 |
Increase, Apoptosis |
leads to |
Decrease, Oogenesis |
1470 |
Decrease, Oogenesis |
leads to |
Decrease, Ovulation |
1471 |
Decrease, Ovulation |
leads to |
Decrease, Fertility |
1472 |
Decrease, Fertility |
leads to |
Decrease, Population trajectory |
1473 |
Increase, angiogenesis |
leads to |
Inhibit, gastric ulcer formation |
1474 |
Increase, platelet aggregation |
leads to |
Inhibit, gastric ulcer formation |
1475 |
Activate, mucosal defense |
leads to |
Inhibit, gastric ulcer formation |
1476 |
Activate, leukocyte |
leads to |
Activated, gastric ulcer formation |
1477 |
Increase, leukocyte adherence |
leads to |
Activate, leukocyte |
1478 |
Activation, PTGS-2 |
leads to |
Decrease, leukocyte adherence |
1479 |
Activation, PTGS-2 |
leads to |
Increase, angiogenesis |
1480 |
Activation, PTGS-1 |
leads to |
Increase, platelet aggregation |
1481 |
Activation, PTGS-1 |
leads to |
Increase, mucosal blood flow |
1482 |
Activation, PTGS-1 |
leads to |
Increase, mucous |
1483 |
Activation, PTGS-1 |
leads to |
Increase, bicarbonate |
1484 |
Increase, bicarbonate |
leads to |
Activate, mucosal defense |
1485 |
Increase, mucous |
leads to |
Activate, mucosal defense |
1486 |
Increase, mucosal blood flow |
leads to |
Activate, mucosal defense |
1487 |
Increase, ammonium (NH4+) |
leads to |
Decrease, surfactant |
1488 |
Activate, phospholipase |
leads to |
Decrease, surfactant |
1489 |
Increase, surfactant |
leads to |
Activate, mucosal defense |
1491 |
Decreased, Population trajectory |
leads to |
Increased Mortality |
1493 |
CYP7B activity, inhibition |
leads to |
7α-hydroxypregnenolone synthesis in the brain, decreased |
1494 |
CYP7B activity, inhibition |
leads to |
Locomotor activity, decreased |
1495 |
7α-hydroxypregnenolone synthesis in the brain, decreased |
leads to |
Locomotor activity, decreased |
1496 |
7α-hydroxypregnenolone synthesis in the brain, decreased |
leads to |
Dopamine release in the brain, decreased |
1497 |
Dopamine release in the brain, decreased |
leads to |
Locomotor activity, decreased |
1498 |
7α-hydroxypregnenolone synthesis in the brain, decreased |
leads to |
Sexual behavior, decreased |
1499 |
Sexual behavior, decreased |
leads to |
Decreased, Reproductive Success |
1500 |
Locomotor activity, decreased |
leads to |
Decreased, Reproductive Success |
1501 |
Decreased, Reproductive Success |
leads to |
Decreased, Population trajectory |
1502 |
Dopamine release in the brain, decreased |
leads to |
Sexual behavior, decreased |
1503 |
Inhibition, Na+/I- symporter (NIS) |
leads to |
Impairment, Learning and memory |
1504 |
TH synthesis, Decreased |
leads to |
BDNF, Reduced |
1505 |
TH synthesis, Decreased |
leads to |
GABAergic interneurons, Decreased |
1506 |
TH synthesis, Decreased |
leads to |
Impairment, Learning and memory |
1507 |
BDNF, Reduced |
leads to |
Impairment, Learning and memory |
1508 |
Inhibition, Calcineurin Activity |
leads to |
Interference, nuclear localization of NFAT |
1509 |
Reduction, NFAT/AP-1 complex formation |
leads to |
Suppression, IL-2 and IL-4 production |
1510 |
Suppression, IL-2 and IL-4 production |
leads to |
Impairment, T-cell dependent antibody response |
1511 |
Inactivated, 5-HTR |
leads to |
Reduced, BDNF |
1512 |
Activation of Cyp2E1 |
leads to |
Oxidative Stress |
1513 |
Oxidative Stress |
leads to |
Hepatocytotoxicity |
1514 |
Hepatocytotoxicity |
leads to |
Sustained proliferation |
1515 |
Activation of Cyp2E1 |
leads to |
Hepatocytotoxicity |
1516 |
Oxidative Stress |
leads to |
Liver Cancer |
1517 |
Hepatocytotoxicity |
leads to |
Liver Cancer |
1518 |
Sustained proliferation |
leads to |
Liver Cancer |
1519 |
Decreased, extracellular serotonin |
leads to |
Decreased, synaptic release |
1520 |
Inhibit, serotonin transporter activity |
leads to |
Decreased, serotonin transporter activity |
1521 |
Increased, extracellular serotonin |
leads to |
Decreased, extracellular serotonin |
1522 |
Increased, glucocorticoid receptor activity |
leads to |
Reduced, BDNF |
1523 |
Reduced, BDNF |
leads to |
Decreased, neuroplasticity |
1524 |
Increased, serotonin transporter activity |
leads to |
Increased, intracellular serotonin |
1525 |
Increased, intracellular serotonin |
leads to |
Increased, packaged serotonin |
1526 |
Increased, packaged serotonin |
leads to |
Increased, synaptic release |
1527 |
Increased, synaptic release |
leads to |
Increased, extracellular serotonin |
1528 |
Increased, serotonin transporter activity |
leads to |
Decreased, extracellular serotonin |
1529 |
Increased, extracellular serotonin |
leads to |
Decreased, 5-HT3 |
1530 |
Decreased, 5-HT3 |
leads to |
Increased, seizure |
1531 |
Increased, extracellular serotonin |
leads to |
Activation, 5-HT2A |
1532 |
Reduced, PTGS1 function |
leads to |
Reduced, platelet aggregation |
1533 |
Reduced, platelet aggregation |
leads to |
Activated, gastric ulcer formation |
1534 |
Reduced, PTGS1 function |
leads to |
Decreased, mucosal blood flow |
1535 |
Decreased, mucosal blood flow |
leads to |
Reduced, mucosal defense |
1536 |
Reduced, mucosal defense |
leads to |
Activated, gastric ulcer formation |
1537 |
Reduced, PTGS1 function |
leads to |
Decreased, mucous |
1538 |
Decreased, mucous |
leads to |
Reduced, mucosal defense |
1539 |
Reduced, PTGS1 function |
leads to |
Decreased, bicarbonate |
1540 |
Decreased, bicarbonate |
leads to |
Reduced, mucosal defense |
1541 |
Reduced, PTGS2 function |
leads to |
Decreased, angiogenesis |
1542 |
Decreased, angiogenesis |
leads to |
Activated, gastric ulcer formation |
1543 |
Reduced, PTGS2 function |
leads to |
Increased, leukocyte adherence |
1544 |
Increased, leukocyte adherence |
leads to |
Increased, leukocyte activation |
1545 |
Increased, leukocyte activation |
leads to |
Activated, gastric ulcer formation |
1546 |
Helicobacter pylori infection |
leads to |
Increase, ammonium (NH4+) |
1547 |
Decrease, surfactant |
leads to |
Reduced, mucosal defense |
1548 |
Reduced, mucosal defense |
leads to |
Helicobacter pylori infection |
1549 |
Increased, hippocampal hyperdepolarization |
leads to |
Increased, seizure |
1550 |
Increased, seizure |
leads to |
Increased, epilepsy |
1551 |
Reduced, presynaptic neuron 2 activity |
leads to |
Decreased, GABA |
1552 |
Decreased, GABA |
leads to |
Reduced, GABA-A receptor activation |
1553 |
Reduced, GABA-A receptor activation |
leads to |
Decreased, intracellular chloride |
1554 |
Decreased, intracellular chloride |
leads to |
Activated, membrane depolarization |
1555 |
Increased, RDX dose |
leads to |
Reduced, GABA-A receptor activation |
1556 |
NFE2/Nrf2 repression |
leads to |
Reduced, FXR activity |
1557 |
Reduced, FXR activity |
leads to |
Reduced, SHP activity |
1558 |
Reduced, SHP activity |
leads to |
Activated, LXR |
1559 |
Activated, LXR |
leads to |
Reduced, PPARalpha |
1560 |
Reduced, PPARalpha |
leads to |
Reduced, HSD17B4 activity |
1561 |
Reduced, HSD17B4 activity |
leads to |
Reduced, fatty acid beta oxidation |
1562 |
Reduced, fatty acid beta oxidation |
leads to |
Increased, steatosis |
1563 |
Mu Opioid Receptor Agonism |
leads to |
Release of G Proteins |
1564 |
Release of G Proteins |
leads to |
Opening of GIRK channels |
1565 |
Opening of GIRK channels |
leads to |
hyperpolarisation, neuron |
1566 |
hyperpolarisation, neuron |
leads to |
Analgesia |
1567 |
Altered, Cardiovascular development/function |
leads to |
Increase, Early Life Stage Mortality |
1568 |
Release of G Proteins |
leads to |
Inhibition of Ca Channels |
1569 |
Inhibition of Ca Channels |
leads to |
Inhibition of neurotransmitter release |
1570 |
Inhibition of neurotransmitter release |
leads to |
Analgesia |
1571 |
Serotonin 1A Receptor Agonism |
leads to |
Release of G Proteins |
1572 |
hyperpolarisation, neuron |
leads to |
Anti-depressant Activity |
1573 |
Inhibition of neurotransmitter release |
leads to |
Anti-depressant Activity |
1574 |
SP (Substance P) release, Local increase of SP |
leads to |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
1575 |
Excitation, Trigeminal nerve excitation |
leads to |
SP (Substance P) release, Local increase of SP |
1576 |
TRPA1 activation, TRPA1 Receptor |
leads to |
Generation of novel epitopes , Antigen presentation |
1577 |
SP (Substance P) release, Local increase of SP |
leads to |
Leukocyte infiltration |
1578 |
Excitation, Trigeminal nerve excitation |
leads to |
Increased CGRP |
1579 |
Increased CGRP |
leads to |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
1580 |
Increased CGRP |
leads to |
Increase, hypertension |
1581 |
Increase, hypertension |
leads to |
Respiratory irritability |
1582 |
Excitation, Trigeminal nerve excitation |
leads to |
Irritation induced sneezing |
1583 |
Excitation, Trigeminal nerve excitation |
leads to |
Increased NKA |
1584 |
Increased NKA |
leads to |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
1585 |
Increased NKA |
leads to |
Leukocyte infiltration |
1586 |
Increased CGRP |
leads to |
Leukocyte infiltration |
1587 |
Increased CGRP |
leads to |
Respiratory irritability |
1588 |
Sensing of the stressor |
leads to |
Pro-inflammatory cytokines increased |
1589 |
Pro-inflammatory cytokines increased |
leads to |
SAA production increased |
1590 |
SAA production increased |
leads to |
HDL-SAA formation |
1591 |
HDL-SAA formation |
leads to |
Systemic cholesterol increased |
1592 |
Systemic cholesterol increased |
leads to |
Foam cell formation |
1593 |
HDL-SAA formation |
leads to |
Foam cell formation |
1594 |
Foam cell formation |
leads to |
Plaque progression |
1595 |
Increase, ROS |
leads to |
Increase, DNA Damage |
1596 |
Increase, Apoptosis |
leads to |
Increase, Follicular atresia |
1597 |
Increase, Follicular atresia |
leads to |
Decrease, Oogenesis |
1598 |
Increase, ROS |
leads to |
Increase, LPO |
1599 |
Increase, LPO |
leads to |
Decrease, Coupling of OXPHOS |
1600 |
Decrease, Coupling of OXPHOS |
leads to |
Decrease, Mitochondrial ATP production |
1601 |
Decrease, Mitochondrial ATP production |
leads to |
Decrease, Oogenesis |
1602 |
Increase, ROS production |
leads to |
Increase, DNA Damage |
1603 |
Increase, ROS production |
leads to |
Increase, LPO |
1606 |
Activation, LXR alpha |
leads to |
Increased, De Novo FA synthesis |
1607 |
Increased, De Novo FA synthesis |
leads to |
Increased, Liver Steatosis |
1608 |
demethylation, PPARg promoter |
leads to |
Activation of specific nuclear receptors, PPAR-gamma activation |
1609 |
Activation of specific nuclear receptors, PPAR-gamma activation |
leads to |
increased adipogenesis |
1610 |
activation of CEBPA |
leads to |
Activation of specific nuclear receptors, PPAR-gamma activation |
1611 |
activation of CEBPA |
leads to |
increased adipogenesis |
1612 |
increased adipogenesis |
leads to |
obesity |
1613 |
chronic high fat diet |
leads to |
decreased dopamine |
1614 |
decreased dopamine |
leads to |
decreased reward |
1615 |
decreased reward |
leads to |
decreased DNA methylation of tyrosine hydroxylase |
1616 |
decreased reward |
leads to |
decreased methylation of dopamine transporter promoter |
1617 |
decreased reward |
leads to |
decreased dopamine |
1618 |
decreased DNA methylation of tyrosine hydroxylase |
leads to |
obesity |
1619 |
decreased methylation of dopamine transporter promoter |
leads to |
obesity |
1620 |
decreased DNA methylation of tyrosine hydroxylase |
leads to |
decreased dopamine |
1621 |
decreased methylation of dopamine transporter promoter |
leads to |
decreased dopamine |
1622 |
Sustained inflammatory cytokine release |
leads to |
Increased, secretion of local growth factors |
1623 |
Increase, ROS production |
leads to |
Increased, secretion of local growth factors |
1624 |
Increased, secretion of local growth factors |
leads to |
Differentiation of fibroblasts |
1625 |
Increased, secretion of local growth factors |
leads to |
EMT |
1626 |
Differentiation of fibroblasts |
leads to |
Expression of Collagen |
1627 |
EMT |
leads to |
Expression of Collagen |
1628 |
Collagen Deposition |
leads to |
Accumulation, Collagen |
1629 |
Accumulation, Collagen |
leads to |
Pulmonary fibrosis |
1630 |
Cell damage sensing |
leads to |
Sustained inflammatory cytokine release |
1631 |
Cell damage sensing |
leads to |
Increase, ROS production |
1632 |
Cell damage sensing |
leads to |
Increased, secretion of local growth factors |
1633 |
Sustained inflammatory cytokine release |
leads to |
Differentiation of fibroblasts |
1634 |
Binding, topoisomerase II |
leads to |
DSB |
1635 |
DSB |
leads to |
MLL translocation |
1636 |
Thiol protein adducts |
leads to |
Inhibition of lysyl oxidase |
1637 |
Inhibition of lysyl oxidase |
leads to |
Reduction of collagen crosslinking |
1638 |
Reduction of collagen crosslinking |
leads to |
Weak collagen matrix |
1639 |
Weak collagen matrix |
leads to |
Notochord malformation |
1640 |
Notochord malformation |
leads to |
Reduced, Swimming performance |
1641 |
Reduced, Swimming performance |
leads to |
Growth, reduction |
1642 |
Reduced, Swimming performance |
leads to |
Decreased, survival |
1643 |
Decrease, histaminergic neuron excitation |
leads to |
Impairment, Learning and memory |
1644 |
Impairment, Learning and memory |
leads to |
Decreased, locomotion |
1645 |
GR Agonist, Activation |
leads to |
Increased apoptosis, decreased Leydig Cells |
1646 |
GR Agonist, Activation |
leads to |
Repressed expression of steroidogenic enzymes |
1647 |
Increased apoptosis, decreased Leydig Cells |
leads to |
Reduction, Testosterone synthesis in Leydig cells |
1648 |
Repressed expression of steroidogenic enzymes |
leads to |
Reduction, Testosterone synthesis in Leydig cells |
1649 |
Reduction, testosterone level |
leads to |
Decreased sperm quantity or quality in the adult, Decreased fertility |
1650 |
Decreased sperm quantity or quality in the adult, Decreased fertility |
leads to |
impaired, Fertility |
1651 |
TGFbeta1 activation |
leads to |
TGFbeta pathway activation |
1652 |
TGFbeta pathway activation |
leads to |
Differentiation of fibroblasts |
1653 |
TGFbeta pathway activation |
leads to |
EMT |
1654 |
Differentiation of fibroblasts |
leads to |
Accumulation, Collagen |
1655 |
EMT |
leads to |
Accumulation, Collagen |
1656 |
Activation, AhR |
leads to |
Up Regulation, SCD-1 |
1657 |
Up Regulation, SCD-1 |
leads to |
Accumulation, Triglyceride |
1658 |
Increased, FA Influx |
leads to |
Increased, Triglyceride formation |
1659 |
demethylation, PPARg promoter |
leads to |
Increased, FA Influx |
1660 |
Decreased, Ketogenesis |
leads to |
Accumulation, Fatty acid |
1661 |
Activation, AKT2 |
leads to |
Activation, SREBF1 |
1662 |
Activation, SREBF1 |
leads to |
Increased, Liver Steatosis |
1663 |
Increase, Uncoupling of photophosphorylation |
leads to |
Decrease, Chloroplast ATP production |
1664 |
Decrease, Chloroplast ATP production |
leads to |
Decrease, Chlorophyll synthesis |
1665 |
Decrease, Chlorophyll synthesis |
leads to |
Decrease, Light harvest capacity |
1666 |
Decrease, Light harvest capacity |
leads to |
Decrease, Photosynthesis |
1667 |
Decrease, Photosynthesis |
leads to |
Decrease, Glycolysis |
1668 |
Decrease, Glycolysis |
leads to |
Decrease, OXPHOS |
1669 |
Decrease, OXPHOS |
leads to |
Decrease, Mitochondrial ATP production |
1670 |
Decrease, Mitochondrial ATP production |
leads to |
Decrease, Leaf cell mitosis |
1671 |
Decrease, Leaf cell mitosis |
leads to |
Decrease, Leaf development |
1672 |
Decrease, Leaf development |
leads to |
Increase, Growth inhibition |
1673 |
Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) |
leads to |
Depletion, mtDNA |
1674 |
Depletion, mtDNA |
leads to |
Dysfunction, Mitochondria |
1675 |
Dysfunction, Mitochondria |
leads to |
Increase, Cytotoxicity (renal tubular cell) |
1676 |
Increase, Cytotoxicity (renal tubular cell) |
leads to |
Occurrence, Kidney toxicity |
1677 |
Binding of substrate, endocytic receptor |
leads to |
Disturbance, Lysosomal function |
1678 |
Disturbance, Lysosomal function |
leads to |
Disruption, Lysosome |
1679 |
Disruption, Lysosome |
leads to |
Increase, Cytotoxicity (renal tubular cell) |
1680 |
Alkylation, Protein |
leads to |
Dysfunction, Mitochondria |
1681 |
Dysfunction, Mitochondria |
leads to |
Decrease, Mitochondrial ATP production |
1682 |
Decrease, Mitochondrial ATP production |
leads to |
Increase, Cytotoxicity (renal tubular cell) |
1683 |
Binding, SH/SeH proteins involved in protection against oxidative stress |
leads to |
N/A, Mitochondrial dysfunction 1 |
1684 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Oxidative Stress |
1685 |
Oxidative Stress |
leads to |
Glutamate dyshomeostasis |
1686 |
Glutamate dyshomeostasis |
leads to |
Cell injury/death |
1687 |
Neuroinflammation |
leads to |
Cell injury/death |
1688 |
Cell injury/death |
leads to |
Neuronal network function, Decreased |
1689 |
Binding, SH/SeH proteins involved in protection against oxidative stress |
leads to |
Oxidative Stress |
1690 |
Oxidative Stress |
leads to |
Cell injury/death |
1691 |
Glutamate dyshomeostasis |
leads to |
Neuronal network function, Decreased |
1692 |
Inhibition of fatty acid beta oxidation |
leads to |
Increase, cytosolic fatty acid |
1693 |
Increase, cytosolic fatty acid |
leads to |
steatohepatitis |
1694 |
Increase, cytosolic fatty acid |
leads to |
Increased, Liver Steatosis |
1695 |
Increased, Liver Steatosis |
leads to |
Increased, Reactive oxygen species |
1696 |
Increased, Reactive oxygen species |
leads to |
increased, oncotic necrosis |
1697 |
increased, oncotic necrosis |
leads to |
steatohepatitis |
1698 |
Peptide Oxidation |
leads to |
S-Glutathionylation, eNOS |
1699 |
Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways |
leads to |
Activation, Dendritic Cells |
1700 |
N/A, Covalent binding to protein, possibly lysine residue |
leads to |
Activation, Dendritic Cells |
1701 |
Activation/Proliferation, T-cells |
leads to |
Increase, Allergic Respiratory Hypersensitivity Response |
1702 |
Interaction with the lung cell membrane |
leads to |
Increased proinflammatory mediators |
1703 |
Increased proinflammatory mediators |
leads to |
Recruitment of inflammatory cells |
1704 |
Recruitment of inflammatory cells |
leads to |
Loss of alveolar capillary membrane integrity |
1705 |
Loss of alveolar capillary membrane integrity |
leads to |
Activation of Th2 cells |
1706 |
Activation of Th2 cells |
leads to |
Increased cellular proliferation and differentiation |
1707 |
Increased cellular proliferation and differentiation |
leads to |
Increased extracellular matrix deposition |
1708 |
Increased extracellular matrix deposition |
leads to |
Pulmonary fibrosis |
1709 |
Histone deacetylase inhibition |
leads to |
Histone acetylation, increase |
1710 |
Histone acetylation, increase |
leads to |
p21 (CDKN1A) expression, increase |
1711 |
p21 (CDKN1A) expression, increase |
leads to |
Cell cycle, disrupted |
1712 |
Cell cycle, disrupted |
leads to |
Apoptosis |
1713 |
Apoptosis |
leads to |
Testicular atrophy |
1714 |
Histone deacetylase inhibition |
leads to |
p21 (CDKN1A) expression, increase |
1715 |
Histone deacetylase inhibition |
leads to |
Cell cycle, disrupted |
1716 |
Histone deacetylase inhibition |
leads to |
Apoptosis |
1717 |
Histone deacetylase inhibition |
leads to |
Testicular atrophy |
1718 |
Cell injury/death |
leads to |
Tissue resident cell activation |
1719 |
Increased pro-inflammatory mediators |
leads to |
Cell injury/death |
1720 |
Activation of PPARγ |
leads to |
Increase, Inflammation |
1721 |
Activation of TGF-β signaling |
leads to |
Increase, Inflammation |
1722 |
Increase, Inflammation |
leads to |
Expression of Collagen |
1723 |
Activation of TGF-β signaling |
leads to |
EMT |
1724 |
Increase, Inflammation |
leads to |
EMT |
1725 |
EMT |
leads to |
Lung fibrosis |
1726 |
CYP2E1 Activation |
leads to |
Oxidative Stress in Brain |
1727 |
Oxidative Stress in Brain |
leads to |
Lipid Peroxidation |
1728 |
Lipid Peroxidation |
leads to |
Protein Adduct Formation |
1729 |
Protein Adduct Formation |
leads to |
Unfolded Prortein Response |
1730 |
Oxidative Stress in Brain |
leads to |
Unfolded Prortein Response |
1731 |
Lipid Peroxidation |
leads to |
General Apoptosis |
1732 |
Unfolded Prortein Response |
leads to |
General Apoptosis |
1733 |
General Apoptosis |
leads to |
Neurodegeneration |
1734 |
Spermatocyte depletion |
leads to |
Testicular atrophy |
1735 |
Apoptosis |
leads to |
Spermatocyte depletion |
1736 |
Increase, D1 protein antagonism |
leads to |
Decrease, PSII activity |
1737 |
Decrease, PSII activity |
leads to |
Decrease, Photosynthesis |
1738 |
Decrease, Glycolysis |
leads to |
Decrease, Mitochondrial ATP production |
1739 |
Decrease, Mitochondrial ATP production |
leads to |
Decrease, Growth |
1740 |
Decrease, PSII activity |
leads to |
Increase, ROS |
1741 |
Increase, Apoptosis |
leads to |
Decrease, Growth |
1742 |
Increase, CHS-1 inhibition |
leads to |
Decrease, Cuticular chitin content |
1743 |
Decrease, Cuticular chitin content |
leads to |
Increase, Premature molting |
1744 |
Increase, Premature molting |
leads to |
Increase, Mortality |
1745 |
Increase, SUR binding |
leads to |
Increase, Cell membrane depolarization |
1746 |
Increase, Cell membrane depolarization |
leads to |
Increase, Opening of voltage-dependent calcium channel |
1747 |
Increase, Opening of voltage-dependent calcium channel |
leads to |
Decrease, Cuticular chitin content |
1748 |
Decreased, PPARalpha transactivation of gene expression |
leads to |
Fatty Acid Beta Oxidation, Decreased |
1749 |
Fatty Acid Beta Oxidation, Decreased |
leads to |
Decreased, Ketogenesis (production of ketone bodies) |
1750 |
Decrease, Mitochondrial ATP production |
leads to |
Increase, Apoptosis |
1751 |
Increase, Apoptosis |
leads to |
Increase, Mortality |
1752 |
Decrease, Oogenesis |
leads to |
Decrease, Fecundity |
1753 |
Decrease, Ovulation |
leads to |
Decrease, Fecundity |
1754 |
Increase, ROS production |
leads to |
Decrease, Coupling of OXPHOS |
1755 |
Blockade, L-Type Calcium Channels |
leads to |
Decrease, Calcium currents |
1756 |
Decrease, Calcium currents |
leads to |
Decrease, Calcium binding to Troponin C |
1757 |
Decrease, Calcium binding to Troponin C |
leads to |
Decrease, Cardiac contractility |
1758 |
Decrease, Cardiac contractility |
leads to |
Decrease, Cardiac ejection fraction |
1759 |
Decrease, Cardiac ejection fraction |
leads to |
Heart failure |
1760 |
Decrease, Calcium currents |
leads to |
Disruption, Intracellular calcium mobilization |
1761 |
Disruption, Intracellular calcium mobilization |
leads to |
Disruption, Sarcomere assembly |
1762 |
Disruption, Sarcomere assembly |
leads to |
Decrease, Cardiac contractility |
1763 |
Tissue resident cell activation |
leads to |
Increased pro-inflammatory mediators |
1764 |
Increased pro-inflammatory mediators |
leads to |
Activation, Stellate cells |
1765 |
Binding, SH/SeH proteins involved in protection against oxidative stress |
leads to |
Protection against oxidative stress, decreased |
1766 |
Protection against oxidative stress, decreased |
leads to |
Oxidative Stress |
1767 |
Inhibition, Aromatase |
leads to |
Altered regulation, Alpha hemoglobin |
1768 |
TH synthesis, Decreased |
leads to |
Reduction, Plasma 17beta-estradiol concentrations |
1769 |
Reduction, Plasma vitellogenin concentrations |
leads to |
Reduction, Cumulative fecundity and spawning |
1770 |
Respiratory irritability |
leads to |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
1771 |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
leads to |
Respiratory irritability |
1772 |
SP (Substance P) release, Local increase of SP |
leads to |
Respiratory irritability |
1773 |
Increased NKA |
leads to |
Respiratory irritability |
1774 |
Irritation induced sneezing |
leads to |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
1775 |
endocytosis |
leads to |
Disruption, Lysosome |
1776 |
Cell injury/death |
leads to |
Increased pro-inflammatory mediators |
1777 |
Increased pro-inflammatory mediators |
leads to |
Leukocyte recruitment/activation |
1778 |
Leukocyte recruitment/activation |
leads to |
Activation, Stellate cells |
1779 |
EMT |
leads to |
Collagen Deposition |
1780 |
Mitochondrial Complex I inhibition |
leads to |
Decrease in mitochondrial oxidative phosphorylation |
1781 |
Increase, Mitochondrial complex III antagonism |
leads to |
Decrease in mitochondrial oxidative phosphorylation |
1782 |
Mitochondrial Complex IV inhibition |
leads to |
Decrease in mitochondrial oxidative phosphorylation |
1783 |
Mitochondrial Complex V inhibition |
leads to |
Decrease in mitochondrial oxidative phosphorylation |
1784 |
Increase, Mitochondrial complex III antagonism |
leads to |
Increased reactive oxygen species (in the mitochondria) |
1785 |
Mitochondrial Complex IV inhibition |
leads to |
Increased reactive oxygen species (in the mitochondria) |
1786 |
Mitochondrial Complex V inhibition |
leads to |
Increased reactive oxygen species (in the mitochondria) |
1787 |
Decrease in mitochondrial oxidative phosphorylation |
leads to |
Mitochondrial Injury |
1788 |
Increased reactive oxygen species (in the mitochondria) |
leads to |
Mitochondrial Injury |
1789 |
Necrotic Tissue |
leads to |
Liver Injury |
1790 |
Mitochondrial Complex I inhibition |
leads to |
Increased reactive oxygen species (in the mitochondria) |
1791 |
Ionizing Energy |
leads to |
DNA DNA double strand breaks |
1792 |
DNA DNA double strand breaks |
leads to |
DNA repair |
1793 |
DNA repair |
leads to |
Increase mutations |
1794 |
DNA repair |
leads to |
Increase chromosomal aberrations |
1795 |
Increase mutations |
leads to |
Increase cell proliferation |
1796 |
Increase chromosomal aberrations |
leads to |
Increase cell proliferation |
1797 |
Increase cell proliferation |
leads to |
Increase, lung cancer |
1798 |
Ionizing Energy |
leads to |
Increase mutations |
1799 |
Ionizing Energy |
leads to |
Increase chromosomal aberrations |
1800 |
Increase mutations |
leads to |
Increase, lung cancer |
1801 |
Increase chromosomal aberrations |
leads to |
Increase, lung cancer |
1802 |
Histone deacetylase inhibition |
leads to |
Reduced neural crest cell migration |
1803 |
Reduced neural crest cell migration |
leads to |
Reduced collagen production |
1804 |
Reduced collagen production |
leads to |
Smaller and morphologically distorted facial cartilage structures |
1805 |
Histone deacetylase inhibition |
leads to |
Reduced collagen production |
1806 |
Histone acetylation, increase |
leads to |
Altered, Gene Expression |
1807 |
Altered, Gene Expression |
leads to |
Altered differentiation |
1808 |
Altered differentiation |
leads to |
Neural tube defects |
1809 |
Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
leads to |
Decrease, OXPHOS |
1810 |
Decrease, OXPHOS |
leads to |
Decreased Na/K ATPase activity |
1811 |
Decreased Na/K ATPase activity |
leads to |
Decreased proximal tubular vectorial transport |
1812 |
Decreased proximal tubular vectorial transport |
leads to |
Chemical induced Fanconi syndrome |
1813 |
Blocking of IL-1R |
leads to |
Impaired IL-1 signaling |
1814 |
Decreased IL-1 production |
leads to |
Impaired IL-1 signaling |
1815 |
Impaired IL-1 signaling |
leads to |
Suppressed AP-1 |
1816 |
Impaired IL-1 signaling |
leads to |
Suppressed NF-kB |
1817 |
Suppressed AP-1 |
leads to |
Suppressed DC activation |
1818 |
Suppressed NF-kB |
leads to |
Suppressed DC activation |
1819 |
Suppressed DC activation |
leads to |
Impaired antigen presentation |
1820 |
Impaired antigen presentation |
leads to |
Impaired T cell activation |
1821 |
Impaired T cell activation |
leads to |
Suppression, Suppression of T-cell dependent antibody response (TDAR) |
1822 |
Impaired T cell activation |
leads to |
Increase, Increased susceptibility to infection |
1823 |
Suppression, Suppression of T-cell dependent antibody response (TDAR) |
leads to |
Increase, Increased susceptibility to infection |
1824 |
Decreased IL-1 production |
leads to |
Suppressed MyD88 |
1825 |
Impaired IL-1 signaling |
leads to |
Suppressed MyD88 |
1826 |
Suppressed MyD88 |
leads to |
Increase, Increased susceptibility to infection |
1827 |
Inhibition, IKK complex |
leads to |
Inhibition, Nuclear factor kappa B (NF-kB) |
1828 |
Inhibition, Nuclear factor kappa B (NF-kB) |
leads to |
Activation, Caspase 8 pathway |
1829 |
Activation, Caspase 8 pathway |
leads to |
Cell injury/death |
1830 |
Cell injury/death |
leads to |
Necrotic Tissue |
1831 |
Cell injury/death |
leads to |
Activation, Tissue resident cells (Kuppfer cells) |
1832 |
Activation, Tissue resident cells (Kuppfer cells) |
leads to |
Increase, proinflammatory mediators (TNFalpha) |
1833 |
Binding of MSAs to microtubules |
leads to |
Disturbance in microtubule dynamic instability |
1834 |
Disturbance in microtubule dynamic instability |
leads to |
Impaired axonial transport |
1835 |
Impaired axonial transport |
leads to |
Sensory axonal peripheral neuropathy |
1836 |
Interaction of α-diketones with arginine residues |
leads to |
Proteasomal dysfunction |
1837 |
Proteasomal dysfunction |
leads to |
Airway epithelial injury |
1838 |
Airway epithelial injury |
leads to |
Increase, Inflammation |
1839 |
Increase, Inflammation |
leads to |
Fibroproliferative airway lesions |
1840 |
EMT |
leads to |
Fibroproliferative airway lesions |
1841 |
Fibroproliferative airway lesions |
leads to |
Bronchiolitis obliterans |
1842 |
Distribution of chemicals |
leads to |
Absorption of photon energy |
1843 |
Absorption of photon energy |
leads to |
ROS generation |
1844 |
Absorption of photon energy |
leads to |
Radical generation |
1845 |
ROS generation |
leads to |
Oxidation of membrane lipids |
1846 |
ROS generation |
leads to |
Oxidation/denatuation of membrane proteins |
1847 |
ROS generation |
leads to |
Oxidation of DNA |
1848 |
Radical generation |
leads to |
DNA photo-adducts |
1849 |
Radical generation |
leads to |
Protein photo-adducts |
1850 |
Oxidation of membrane lipids |
leads to |
Inflammatory events |
1851 |
Oxidation/denatuation of membrane proteins |
leads to |
Inflammatory events |
1852 |
Oxidation of DNA |
leads to |
Inflammatory events |
1853 |
DNA photo-adducts |
leads to |
Inflammatory events |
1854 |
Protein photo-adducts |
leads to |
Inflammatory events |
1855 |
Inflammatory events |
leads to |
Eczematous eruption |
1856 |
Eczematous eruption |
leads to |
Scaling, Lichenification |
1857 |
ACh Synaptic Accumulation |
leads to |
Activation, Muscarinic Acetylcholine Receptors |
1858 |
Activation, Muscarinic Acetylcholine Receptors |
leads to |
Increased, glutamate |
1859 |
Increased, glutamate |
leads to |
Overactivation, NMDARs |
1860 |
Increased, Intracellular Calcium overload |
leads to |
Occurrence, Epileptic seizure |
1861 |
Occurrence, Epileptic seizure |
leads to |
Increased, glutamate |
1862 |
Increased, Intracellular Calcium overload |
leads to |
Cell injury/death |
1863 |
Cell injury/death |
leads to |
Neurodegeneration |
1864 |
Inhibition of N-linked glycosylation |
leads to |
Accumulation, misfolded proteins |
1865 |
Accumulation, misfolded proteins |
leads to |
Unfolded Prortein Response |
1866 |
Unfolded Prortein Response |
leads to |
Apoptosis |
1867 |
Apoptosis |
leads to |
Activation, hepatic stellate cells |
1868 |
Activation, hepatic stellate cells |
leads to |
Liver Injury |
1869 |
Apoptosis |
leads to |
Liver Injury |
1870 |
Suppressed MyD88 |
leads to |
Inhibition, Nuclear factor kappa B (NF-kB) |
1871 |
Inhibition, Nuclear factor kappa B (NF-kB) |
leads to |
Increase, Increased susceptibility to infection |
1872 |
Increase, Mitochondrial complex III antagonism |
leads to |
Decrease, OXPHOS |
1873 |
Decrease, Mitochondrial ATP production |
leads to |
Increase, Necrosis |
1874 |
Increase, Necrosis |
leads to |
Increase, Mortality |
1875 |
Increase, Mitochondrial complex III antagonism |
leads to |
Increase, ROS |
1876 |
Increase, ROS |
leads to |
Increase,Oxidative DNA damage |
1877 |
Increase,Oxidative DNA damage |
leads to |
Increase, Apoptosis |
1878 |
Inhibition of Cyp17A1 activity |
leads to |
Reduction, DHEA |
1879 |
Inhibition of Cyp17A1 activity |
leads to |
Reduction, androstenedione |
1880 |
5α-reductase, inhibition |
leads to |
Decrease, DHT level |
1881 |
Decrease, DHT level |
leads to |
Reduction, Plasma 17beta-estradiol concentrations |
1882 |
Reduction, Plasma vitellogenin concentrations |
leads to |
Reduction, egg production and spawning |
1883 |
Increase, DNMT inhibition |
leads to |
Increase, DNA hypomethylation |
1884 |
Increase, DNA hypomethylation |
leads to |
Increase, Gene expression |
1885 |
Increase, Gene expression |
leads to |
Decrease, Fecundity |
1886 |
Decrease, Fecundity |
leads to |
Decrease, Population trajectory |
1887 |
Increase, DNA hypomethylation |
leads to |
Decrease, Transgenerational DNA methylation |
1888 |
Decrease, Transgenerational DNA methylation |
leads to |
Increase, Gene expression |
1889 |
Activation, Muscarinic Acetylcholine Receptors |
leads to |
Occurrence, Focal Seizure |
1890 |
Occurrence, Focal Seizure |
leads to |
Increased, glutamate |
1891 |
tyrosinase |
leads to |
Reduction of L-Dopaquinone |
1892 |
Reduction of L-Dopaquinone |
leads to |
Reduction in melanin level |
1893 |
Reduction in melanin level |
leads to |
Reduction of melanosome level |
1894 |
Reduction of melanosome level |
leads to |
Reduction fo Pigmentation pattern |
1895 |
Reduction fo Pigmentation pattern |
leads to |
Decrease, Population trajectory |
1896 |
Increase, Mutations |
leads to |
Increase, Cell Proliferation (Epithelial Cells) |
1897 |
Increase, DNA Damage |
leads to |
Increase, Mutations |
1898 |
Increase, DNA Damage |
leads to |
Tissue resident cell activation |
1899 |
Increase, DNA Damage |
leads to |
Increase mutations |
1900 |
Increase mutations |
leads to |
Increase, Cell Proliferation (Epithelial Cells) |
1901 |
Leukocyte recruitment/activation |
leads to |
Increase, Cell Proliferation (Epithelial Cells) |
1902 |
Increased pro-inflammatory mediators |
leads to |
N/A, Breast Cancer |
1903 |
Increased pro-inflammatory mediators |
leads to |
Increase in RONS |
1904 |
Increase in RONS |
leads to |
Increase, DNA Damage |
1905 |
Leukocyte recruitment/activation |
leads to |
Increase in RONS |
1906 |
Increase in RONS |
leads to |
Tissue resident cell activation |
1907 |
Increase, Cell Proliferation (Epithelial Cells) |
leads to |
Increase, Mutations |
1908 |
Increased pro-inflammatory mediators |
leads to |
Increase, Cell Proliferation (Epithelial Cells) |
1909 |
Increase, Oxidative DNA damage |
leads to |
N/A, Inadequate DNA repair |
1910 |
N/A, Inadequate DNA repair |
leads to |
Increase, DNA strand breaks |
1911 |
Increase, DNA strand breaks |
leads to |
N/A, Inadequate DNA repair |
1912 |
N/A, Inadequate DNA repair |
leads to |
Increase, Chromosomal aberrations |
1913 |
Increase, Oxidative DNA damage |
leads to |
Increase, DNA strand breaks |
1914 |
Increase, Oxidative DNA damage |
leads to |
Increase, Mutations |
1915 |
Retinaldehyde dehydrogenase |
leads to |
retinoic acid |
1916 |
retinoic acid |
leads to |
plasma retionic acid |
1917 |
plasma retionic acid |
leads to |
Optical elements of the eye |
1918 |
Optical elements of the eye |
leads to |
Visual impairment |
1919 |
Visual impairment |
leads to |
Decline, Population |
1920 |
Impaired IL-1 signaling |
leads to |
Inhibition, Nuclear factor kappa B (NF-kB) |
1921 |
Inhibition, Nuclear factor kappa B (NF-kB) |
leads to |
Impaired T cell activation |
1922 |
Impaired T cell activation |
leads to |
Impaired Ab production |
1923 |
Impaired Ab production |
leads to |
Increase, Increased susceptibility to infection |
1924 |
Wnt ligand stimulation |
leads to |
Frizzled activation |
1925 |
Frizzled activation |
leads to |
GSK3beta inactivation |
1926 |
GSK3beta inactivation |
leads to |
β-catenin activation |
1927 |
β-catenin activation |
leads to |
Snail, Zeb, Twist activation |
1928 |
Snail, Zeb, Twist activation |
leads to |
Epithelial-mesenchymal transition |
1929 |
Epithelial-mesenchymal transition |
leads to |
Resistant gastric cancer |
1930 |
Increase, SAM depletion |
leads to |
Increase, DNA hypomethylation |
1931 |
Increase, DNA strand breaks |
leads to |
Increase, Mutations |
1932 |
Reduction, DHEA |
leads to |
Decrease, testosterone level |
1933 |
Reduction, androstenedione |
leads to |
Decrease, testosterone level |
1934 |
Decrease, testosterone level |
leads to |
Decrease, DHT level |
1935 |
Decrease, DHT level |
leads to |
Decrease, AR activation |
1936 |
Decrease, testosterone level |
leads to |
Decrease, AR activation |
1937 |
Decrease, AR activation |
leads to |
Impaired inguinoscrotal phase |
1938 |
Impaired inguinoscrotal phase |
leads to |
Malformation, cryptorchidism |
1939 |
Increase, DNA strand breaks |
leads to |
Increase, Chromosomal aberrations |
1940 |
Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
leads to |
Decrease in mitochondrial oxidative phosphorylation |
1941 |
Mitochondrial Injury |
leads to |
Increased reactive oxygen species (in the mitochondria) |
1942 |
Mitochondrial Injury |
leads to |
Impaired, Proteostasis |
1943 |
Impaired, Proteostasis |
leads to |
Cell injury/death |
1944 |
Binding of inhibitor, mitochondrial complex III |
leads to |
Increase, Mitochondrial complex III antagonism |
1945 |
Binding of inhibitor, mitochondrial complex IV |
leads to |
Mitochondrial Complex IV inhibition |
1946 |
Binding of inhibitor, mitochondrial complex V |
leads to |
Mitochondrial Complex V inhibition |
1947 |
TR Antagnoism |
leads to |
Hippocampal gene expression, Altered |
1948 |
TR Antagnoism |
leads to |
Cognitive Function, Decreased |
1949 |
CBS inhibition |
leads to |
Homocysteine increases |
1950 |
MTHFR inhibition |
leads to |
Homocysteine increases |
1951 |
Methionine synthase |
leads to |
Homocysteine increases |
1952 |
betaine-homocysteine methyltransferase inhibition |
leads to |
Homocysteine increases |
1953 |
Homocysteine increases |
leads to |
plasma homocysteine increases |
1954 |
plasma homocysteine increases |
leads to |
brain Homocysteine level increases |
1955 |
brain Homocysteine level increases |
leads to |
Neuronal dysfunctions induction |
1956 |
Decrease in mitochondrial oxidative phosphorylation |
leads to |
N/A, Mitochondrial dysfunction 1 |
1957 |
Increased reactive oxygen species (in the mitochondria) |
leads to |
N/A, Mitochondrial dysfunction 1 |
1958 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Increased reactive oxygen species (in the mitochondria) |
1959 |
Homocysteine increases |
leads to |
Plasma HCY level |
1960 |
Plasma HCY level |
leads to |
dysfunction of microcirculation |
1961 |
dysfunction of microcirculation |
leads to |
anterior-posterior axis development |
1962 |
Frustrated phagoytosis |
leads to |
Release, Cytokine |
1963 |
Release, Cytokine |
leads to |
Recruitment of inflammatory cells |
1964 |
Recruitment of inflammatory cells |
leads to |
Increased, Reactive oxygen species |
1965 |
Increased, Reactive oxygen species |
leads to |
Increased, DNA damage and mutation |
1966 |
Increased, DNA damage and mutation |
leads to |
Increase, Cell Proliferation |
1967 |
Increase, Cell Proliferation |
leads to |
Lung cancer |
1968 |
Substance - LS interaction |
leads to |
Inhibition of LS function. |
1969 |
Inhibition of LS function. |
leads to |
Alveolar collapse |
1970 |
Alveolar collapse |
leads to |
Alveolar reopening |
1971 |
Alveolar reopening |
leads to |
Loss of barrier function |
1972 |
Loss of barrier function |
leads to |
Blood extravasation into the lungs |
1973 |
Blood extravasation into the lungs |
leads to |
Acute inhalation toxicity |
1974 |
Alveolar collapse |
leads to |
Reduced lung volume |
1975 |
Reduced lung volume |
leads to |
Impaired oxygenation of the blood |
1976 |
Impaired oxygenation of the blood |
leads to |
Acute inhalation toxicity |
1977 |
Energy Deposition |
leads to |
Increase, DNA strand breaks |
1978 |
Increase, Mutations |
leads to |
Increase, Cell Proliferation |
1979 |
Increase, Chromosomal aberrations |
leads to |
Increase, Cell Proliferation |
1980 |
Increase, Cell Proliferation |
leads to |
Increase, lung cancer |
1981 |
Energy Deposition |
leads to |
Increase, Mutations |
1982 |
Energy Deposition |
leads to |
Increase, Chromosomal aberrations |
1983 |
Energy Deposition |
leads to |
Increase, lung cancer |
1984 |
Increase, Mutations |
leads to |
Increase, lung cancer |
1985 |
Increase, Chromosomal aberrations |
leads to |
Increase, lung cancer |
1986 |
Antagonism,LH receptor |
leads to |
Reduction, Progesterone synthesis |
1987 |
Reduction, Progesterone synthesis |
leads to |
Reduction, Plasma progesterone concentration |
1988 |
Reduction, Plasma progesterone concentration |
leads to |
Reduction, progesterone uptake, decresed maturation |
1989 |
Reduction, progesterone uptake, decresed maturation |
leads to |
Impaired ovulation |
1990 |
Impaired ovulation |
leads to |
Decrease of egg production and cummulative fecundity |
1991 |
Decrease of egg production and cummulative fecundity |
leads to |
Decline, Population trajectory |
1992 |
Activation, AhR |
leads to |
Increase, DNMT expression |
1993 |
Increase, DNMT expression |
leads to |
Increase, hypermethylation of the promotor region of GnRHR |
1994 |
Increase, hypermethylation of the promotor region of GnRHR |
leads to |
Decease, expression of GnRHR |
1995 |
Decease, expression of GnRHR |
leads to |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
1996 |
dimerization, AHR/ARNT |
leads to |
Increase, DNMT expression |
1997 |
Histone acetylation, increase |
leads to |
Cell cycle, disrupted |
1998 |
Occurrence, Focal Seizure |
leads to |
Overactivation, NMDARs |
1999 |
Occurrence, Epileptic seizure |
leads to |
Overactivation, NMDARs |
2000 |
Impaired IL-1R1 signaling |
leads to |
Suppression of T cell activation |
2001 |
Suppression of T cell activation |
leads to |
Inhibition, Nuclear factor kappa B (NF-kB) |
2002 |
Impaired IL-1R1 signaling |
leads to |
Inhibition, Nuclear factor kappa B (NF-kB) |
2003 |
Inhibition, Nuclear factor kappa B (NF-kB) |
leads to |
Suppression of T cell activation |
2004 |
Suppression of T cell activation |
leads to |
Increase, Increased susceptibility to infection |
2005 |
Increased Cholinergic Signaling |
leads to |
Cardiovascular dysregulation |
2006 |
Cardiovascular dysregulation |
leads to |
Respiratory distress/arrest |
2007 |
AchE Inhibition |
leads to |
Cardiovascular dysregulation |
2008 |
Oxidative Stress |
leads to |
Wnt ligand stimulation |
2009 |
Increased, Reactive oxygen species |
leads to |
Oxidative Stress |
2010 |
Histone deacetylase inhibition |
leads to |
Spermatocyte depletion |
2011 |
Increased Cholinergic Signaling |
leads to |
Impaired coordination and movement |
2012 |
Impaired coordination and movement |
leads to |
Increased Mortality |
2013 |
Increased Mortality |
leads to |
Decrease, Population trajectory |
2014 |
AchE Inhibition |
leads to |
Impaired coordination and movement |
2015 |
Impaired coordination and movement |
leads to |
Decrease, Population trajectory |
2016 |
AchE Inhibition |
leads to |
Decrease, Population trajectory |
2017 |
Stimulation of TLR7/8 |
leads to |
Increase of IL-23 |
2018 |
Increase of IL-23 |
leads to |
Th17 cell migration and inflammation induction |
2019 |
Th17 cell migration and inflammation induction |
leads to |
Skin disease |
2020 |
Binding to estrogen receptor (ER)-α |
leads to |
Induction of GATA3 expression |
2021 |
Induction of GATA3 expression |
leads to |
Increase of Th2 cells producing IL-4 |
2022 |
Increase of Th2 cells producing IL-4 |
leads to |
Increase of autoantibody production |
2023 |
Increase of autoantibody production |
leads to |
Exacerbation of SLE |
2024 |
Inhibition of JAK3 |
leads to |
STAT5 inhibition |
2025 |
STAT5 inhibition |
leads to |
Suppression of STAT5 binding |
2026 |
Suppression of STAT5 binding |
leads to |
Suppression of IL-4 production |
2027 |
Suppression of IL-4 production |
leads to |
Impairment, TDAR |
2028 |
Inhibition, trypsin |
leads to |
Increased monitor peptide |
2029 |
Increased monitor peptide |
leads to |
Increased blood CCK level |
2030 |
Increased blood CCK level |
leads to |
Increased acinar cell exocrine secretion |
2031 |
Increased acinar cell exocrine secretion |
leads to |
Acinar cell proliferation |
2032 |
Acinar cell proliferation |
leads to |
Acinar cell tumors |
2033 |
Increased, Reactive oxygen species |
leads to |
β-catenin activation |
2034 |
test |
leads to |
Unknown, MIE |
2035 |
Unknown, MIE |
leads to |
Unknown, |
2036 |
Unknown, MIE |
leads to |
N/A, Unknown |
2037 |
test |
leads to |
N/A, Unknown |
2038 |
T4 in serum, Decreased |
leads to |
Decreased, Triiodothyronine (T3) in serum |
2039 |
Activation, Glucocorticoid Receptor |
leads to |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
2040 |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
leads to |
Increased, Liver Steatosis |
2041 |
Activation, Glucocorticoid Receptor |
leads to |
Decreased, PPAR-alpha activation |
2042 |
Decreased, PPAR-alpha activation |
leads to |
Increased, Liver Steatosis |
2052 |
Increased viral entry and gene expression |
leads to |
Increased proinflammatory mediators |
2053 |
Increased proinflammatory mediators |
leads to |
Pro-inflammatory cytokines increased |
2056 |
ACE2 binding to viral S-protein |
leads to |
Increased viral entry and gene expression |
2061 |
Increased proinflammatory mediators |
leads to |
Increased inflammatory immune responses |
2062 |
Increased inflammatory immune responses |
leads to |
Increase, the risk of acute respiratory failure |
2064 |
Increase, the risk of acute respiratory failure |
leads to |
Decreased mortality |
2065 |
ACE2 inhibition |
leads to |
Increases AngII |
2066 |
Increases AngII |
leads to |
Increase plasma Ang II |
2067 |
Increase plasma Ang II |
leads to |
Increase,collagen synthesis |
2068 |
Increase,collagen synthesis |
leads to |
Induction lung fibrosis |
2069 |
Chronic ROS |
leads to |
Sustained tissue damage / macrophage activation/ porcupine-induced Wnt secretion |
2070 |
Sustained tissue damage / macrophage activation/ porcupine-induced Wnt secretion |
leads to |
Proliferation/ beta-catenin activation |
2071 |
Proliferation/ beta-catenin activation |
leads to |
Epithelial-mesenchymal transition |
2072 |
Decreased, cholesterol |
leads to |
Decreased, 11KT |
2073 |
Activation, PPARα |
leads to |
Decreased, cholesterol |
2074 |
Increase, DNA strand breaks |
leads to |
Increase, Apoptosis |
2075 |
Increase, Apoptosis |
leads to |
Reduce, Sperm count |
2076 |
Decreased, 11KT |
leads to |
Impaired, Spermatogenesis |
2077 |
Activation, Glucocorticoid Receptor |
leads to |
Increase, Cripto-1 expression |
2078 |
Increase, Cripto-1 expression |
leads to |
Inhibition, Activin signaling |
2079 |
Inhibition, Activin signaling |
leads to |
Inhibition, Fin regeneration |
2080 |
Inhibition, Fin regeneration |
leads to |
Reduced, Swimming performance |
2081 |
Reduced, Swimming performance |
leads to |
Decrease, Population trajectory |
2082 |
Increase, Cripto-1 expression |
leads to |
Inhibition, Fin regeneration |
2083 |
Mitochondrial impairment |
leads to |
cell injury |
2084 |
cell injury |
leads to |
Increase, Regenerative cell proliferation (urothelial cells) |
2085 |
Increase, Hyperplasia (urothelial) |
leads to |
carcinogenicity |
2087 |
Increase, Formation of DNA photoproducts |
leads to |
Increase, DNA DSB |
2088 |
Increase, DNA DSB |
leads to |
Increase, Apoptosis |
2089 |
Increase, ROS production |
leads to |
Increase, Protein oxidation |
2090 |
Increase, Protein oxidation |
leads to |
Increase, Abnormal osmoregulation |
2091 |
Increase, Abnormal osmoregulation |
leads to |
Increase, Body fluid overload |
2092 |
Increase, Body fluid overload |
leads to |
Increase, Mortality |
2093 |
Increase, ROS production |
leads to |
Decrease, MMP |
2094 |
Decrease, MMP |
leads to |
Decrease, OXPHOS |
2095 |
Decrease, OXPHOS |
leads to |
Decrease, ATP pool |
2096 |
Decrease, ATP pool |
leads to |
Increase, Mortality |
2097 |
Increase, LPO |
leads to |
Decrease, Neutral lipids |
2098 |
Decrease, Neutral lipids |
leads to |
Decrease, ATP pool |
2099 |
Increase, ROS production |
leads to |
Increase,Oxidative DNA damage |
2100 |
Increase,Oxidative DNA damage |
leads to |
Increase, DNA DSB |
2101 |
Increase, DNMT inhibition |
leads to |
Decrease, Global DNA methylation |
2102 |
Decrease, Global DNA methylation |
leads to |
Increase, Casp transcription |
2103 |
Increase, Casp transcription |
leads to |
Increase, Oocyte apoptosis |
2104 |
Increase, Oocyte apoptosis |
leads to |
Decrease, Oogenesis |
2105 |
Increase, Casp transcription |
leads to |
Increase, Ovarian somatic cell apoptosis |
2106 |
Increase, Ovarian somatic cell apoptosis |
leads to |
Increase, Ovarian follicle breakdown |
2107 |
Increase, Ovarian follicle breakdown |
leads to |
Decrease, Oogenesis |
2108 |
Increase, DNMT inhibition |
leads to |
Increase, DNA DSB |
2109 |
Increase, DNA DSB |
leads to |
Increase, Casp transcription |
2110 |
Decrease, Global DNA methylation |
leads to |
Decrease, Heritable DNA methylation (F3) |
2111 |
Decrease, Heritable DNA methylation (F3) |
leads to |
Increase, Casp transcription (F3) |
2112 |
Increase, Casp transcription (F3) |
leads to |
Increase, Oocyte apoptosis (F3) |
2113 |
Increase, Oocyte apoptosis (F3) |
leads to |
Decrease, Oogenesis (F3) |
2114 |
Decrease, Oogenesis (F3) |
leads to |
Decrease, Fecundity (F3) |
2115 |
Decrease, Fecundity (F3) |
leads to |
Decrease, Population trajectory |
2116 |
Increase, Casp transcription (F3) |
leads to |
Increase, Ovarian somatic cell apoptosis (F3) |
2117 |
Increase, Ovarian somatic cell apoptosis (F3) |
leads to |
Increase, Ovarian follicle breakdown (F3) |
2118 |
Increase, Ovarian follicle breakdown (F3) |
leads to |
Decrease, Oogenesis (F3) |
2119 |
Increase, Mitochondrial ATP synthase antagonism |
leads to |
Decrease, OXPHOS |
2120 |
Decrease, ATP pool |
leads to |
Increase, Oocyte apoptosis |
2121 |
Decrease, ATP pool |
leads to |
Increase, Necrosis |
2122 |
Increase, Necrosis |
leads to |
Increase, Ovarian follicle breakdown |
2123 |
Antagonism, Androgen receptor |
leads to |
short male AGD |
2124 |
Decrease, AR activation |
leads to |
Altered, Transcription of genes by AR |
2125 |
Reduction, Testosterone synthesis in Leydig cells |
leads to |
reduction, testosterone levels |
2126 |
reduction, testosterone levels |
leads to |
Decrease, DHT level |
2127 |
Altered, Transcription of genes by AR |
leads to |
short male AGD |
2128 |
Decrease, AR activation |
leads to |
decrease, transcription of genes by AR |
2129 |
decrease, transcription of genes by AR |
leads to |
short male AGD |
2130 |
Antagonism, Androgen receptor |
leads to |
Decrease, AR activation |
2131 |
reduction, testosterone levels |
leads to |
Decrease, AR activation |
2132 |
Altered, Transcription of genes by AR |
leads to |
nipple retention (NR) male |
2133 |
Antagonism, Androgen receptor |
leads to |
nipple retention (NR) male |
2134 |
Activation, PPARα |
leads to |
Decreased, 11KT |
2135 |
Increase, the risk of acute respiratory failure |
leads to |
Increased Mortality |
2136 |
ACE2 agonism |
leads to |
Increase plasma Ang II |
2137 |
ACE2 agonism |
leads to |
Increases AngII |
2138 |
Increase plasma Ang II |
leads to |
Accumulation, Collagen |
2139 |
Accumulation, Collagen |
leads to |
Lung fibrosis |
2140 |
Increased, Intracellular Calcium overload |
leads to |
Status epilepticus |
2141 |
Status epilepticus |
leads to |
Overactivation, NMDARs |
2142 |
Reduction, Cumulative fecundity and spawning |
leads to |
Decline, Population |
2143 |
Visual impairment |
leads to |
Decrease, Population trajectory |
2144 |
Inhibition, Aromatase |
leads to |
Reduction, E2 Synthesis by the undifferentiated gonad |
2145 |
Reduction, E2 Synthesis by the undifferentiated gonad |
leads to |
Increased, Differentiation to Testis |
2146 |
Increased, Differentiation to Testis |
leads to |
Increased, Male Biased Sex Ratio |
2147 |
Increased, Male Biased Sex Ratio |
leads to |
Decrease, Population trajectory |
2148 |
TLR4 activation |
leads to |
Activation, JNK |
2149 |
Activation, JNK |
leads to |
AP-1 activation |
2150 |
Activation, JNK |
leads to |
Pin-1 activation |
2151 |
Pin-1 activation |
leads to |
TGFbeta expression |
2152 |
TGFbeta expression |
leads to |
Activation, TGF-beta pathway |
2153 |
Activation, TGF-beta pathway |
leads to |
EMT |
2154 |
EMT |
leads to |
Pulmonary fibrosis |
2155 |
TLR4 activation |
leads to |
Activation, TGF-beta pathway |
2156 |
Inactivation of PPARγ |
leads to |
Activation, TGF-beta pathway |
2157 |
AP-1 activation |
leads to |
TGFbeta expression |
2158 |
11β-hydroxylase inhibition |
leads to |
Decreased, 11KT |
2161 |
Decreased size and sperm volume |
leads to |
impaired, Fertility |
2162 |
Inhibition of 11β-HSD |
leads to |
Decreased, 11KT |
2164 |
Impaired, Spermatogenesis |
leads to |
Decrease, Fertility |
2165 |
Decreased, 11KT |
leads to |
Decrease, Fertility |
2166 |
Decreased, 11KT |
leads to |
Decreased size and sperm volume |
2167 |
Inhibition, Aromatase |
leads to |
Increased, Differentiation to Testis |
2168 |
T4 in serum, Decreased |
leads to |
Altered, Amphibian metamorphosis |
2169 |
Decrease, Growth |
leads to |
Decrease, Population trajectory |
2170 |
Increase, Chitinase inhibition |
leads to |
Decrease, Digestion of old cuticle |
2171 |
Decrease, Digestion of old cuticle |
leads to |
Increase, Premature molting |
2172 |
Increase, Chitobiase inhibition |
leads to |
Decrease, Digestion of old cuticle |
2173 |
Alveolar reopening |
leads to |
Loss of alveolar capillary membrane integrity |
2174 |
Loss of alveolar capillary membrane integrity |
leads to |
Blood extravasation into the lungs |
2175 |
Decrease, Coupling of OXPHOS |
leads to |
Decrease, ATP synthase activity |
2176 |
Decrease, ATP synthase activity |
leads to |
Decrease, ATP pool |
2177 |
Increase, Necrosis |
leads to |
Increase, Tissue/organ damage |
2178 |
Increase, Tissue/organ damage |
leads to |
Decrease, Growth |
2179 |
Decrease, ATP pool |
leads to |
Decrease, ATPase activity |
2180 |
Decrease, ATPase activity |
leads to |
Increase, Abnormal osmoregulation |
2181 |
Increase, Abnormal osmoregulation |
leads to |
Increase, Tissue/organ damage |
2182 |
Decrease, Coupling of OXPHOS |
leads to |
Increase, Complex III dysfunction |
2183 |
Increase, Complex III dysfunction |
leads to |
Increase, Cyt c release |
2184 |
Increase, Cyt c release |
leads to |
Increase, Apoptosis |
2185 |
Increase, Apoptosis |
leads to |
Increase, Tissue/organ damage |
2186 |
Increase, Complex III dysfunction |
leads to |
Increase, ROS production |
2187 |
Increase, ROS production |
leads to |
Increase, Apoptosis |
2188 |
Decrease, Coupling of OXPHOS |
leads to |
Increase, Complex I dysfunction |
2189 |
Increase, Complex I dysfunction |
leads to |
Increase, ROS production |
2190 |
Increase,Oxidative DNA damage |
leads to |
Apoptosis |
2191 |
Apoptosis |
leads to |
Increase, Tissue/organ damage |
2192 |
Reactive Metabolite |
leads to |
Mitochondrial dysfunction |
2193 |
Mitochondrial dysfunction |
leads to |
Apoptotic cell death |
2194 |
Reactive Metabolite |
leads to |
Immune cell activation |
2195 |
Mitochondrial dysfunction |
leads to |
ER stress |
2196 |
Immune cell activation |
leads to |
IFNγ signaling |
2197 |
IFNγ signaling |
leads to |
Increase in inflammation |
2198 |
Apoptotic cell death |
leads to |
Increase in inflammation |
2199 |
Increase in inflammation |
leads to |
hepatitis |
2200 |
ER stress |
leads to |
Apoptotic cell death |
2201 |
Antagonism, Androgen receptor |
leads to |
Altered, Transcription of genes by AR |
2202 |
Covalent Binding, Protein |
leads to |
Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways |
2203 |
Decrease, Coupling of OXPHOS |
leads to |
Decrease, ATP pool |
2204 |
Decrease, ATP pool |
leads to |
Decrease, Cell proliferation |
2205 |
Decrease, Cell proliferation |
leads to |
Decrease, Growth |
2206 |
Increase, LPO |
leads to |
Decrease, Lipid storage |
2207 |
Decrease, Lipid storage |
leads to |
Decrease, FAO |
2208 |
Decrease, FAO |
leads to |
Decrease, ATP pool |
2209 |
Decrease, ATP pool |
leads to |
Decrease, Oogenesis |
2210 |
Increase, LPO |
leads to |
Increase, Apoptosis |
2211 |
Increase, Follicular atresia |
leads to |
Decrease, Fecundity |
2212 |
Reduced, Swimming performance |
leads to |
Increased Mortality |
2213 |
Reduced, Posterior swim bladder inflation |
leads to |
Increased Mortality |
2214 |
Decrease, ATP pool |
leads to |
Increase, Cell death |
2215 |
Increase, Cell death |
leads to |
Decrease, Growth |
2216 |
Decrease, ATP pool |
leads to |
Increase, Fatty acid β-oxidation |
2217 |
Increase, Fatty acid β-oxidation |
leads to |
Decrease, Lipid storage |
2218 |
Decrease, Lipid storage |
leads to |
Decrease, Growth |
2219 |
Decrease, Coupling of OXPHOS |
leads to |
Increase, Oxygen consumption |
2220 |
Increase, Oxygen consumption |
leads to |
Increase, ROS production |
2221 |
Increase,Oxidative DNA damage |
leads to |
Increase, Cell death |
2222 |
Increase, LPO |
leads to |
Increase, Cell death |
2223 |
Increase, Protein oxidation |
leads to |
Increase, Cell death |
2224 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Increase, ROS production |
2225 |
Increase, ROS production |
leads to |
Increase, Global methylation |
2226 |
Increase, Global methylation |
leads to |
Increase, Apoptosis |
2227 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Increase, ROS |
2228 |
N/A, Mitochondrial dysfunction 1 |
leads to |
Decrease, ATP pool |
2229 |
Increase, Mitochondrial ATP synthase antagonism |
leads to |
Decrease, ATP pool |
2230 |
Increase, Mitochondrial complex III antagonism |
leads to |
Decrease, ATP pool |
2231 |
Reduced, Hearing |
leads to |
Increased Mortality |
2232 |
Inhibition, Na+/I- symporter (NIS) |
leads to |
T4 in serum, Decreased |
2233 |
Inhibition, Iodotyrosine deiodinase (IYD) |
leads to |
Decreased, Thyroxine (T4) in serum |
2234 |
Decreased, Thyroxine (T4) in serum |
leads to |
Altered, Amphibian metamorphosis |
2235 |
Induction, Upregulation of glucuronyltransferase activity |
leads to |
Increase, Biliary excretion TH glucuronide |
2236 |
Increase, Biliary excretion TH glucuronide |
leads to |
T4 in serum, Decreased |
2237 |
Increased, Hepatic thyroid hormone uptake/transport |
leads to |
T4 in serum, Decreased |
2238 |
Decreased, Triiodothyronine (T3) in tissues |
leads to |
Increased, Thyroid-stimulating hormone (TSH) |
2239 |
Decreased, Triiodothyronine (T3) in tissues |
leads to |
Altered, TH-dependent gene expression |
2240 |
Increased, Thyroid-stimulating hormone (TSH) |
leads to |
Increased, Thyroxine (T4) in serum |
2241 |
Increased, Thyroxine (T4) in serum |
leads to |
Altered, Amphibian metamorphosis |
2242 |
Increased, Thyroxine (T4) in serum |
leads to |
Altered, TH-dependent gene expression |
2243 |
Increased, Triiodothyronine (T3) in tissues |
leads to |
Altered, TH-dependent gene expression |
2244 |
Altered, TH-dependent gene expression |
leads to |
Altered, Amphibian metamorphosis |
2245 |
Binding, Transthyretin in serum |
leads to |
Displacement, Serum thyroxine (T4) from transthyretin |
2246 |
Displacement, Serum thyroxine (T4) from transthyretin |
leads to |
Increased, Free serum thyroxine (T4) |
2247 |
Increased, Free serum thyroxine (T4) |
leads to |
Increased, Hepatic thyroid hormone uptake/transport |
2248 |
Binding, Transthyretin in serum |
leads to |
Displacement, Serum thyroxine (T4) from carrier protein |
2249 |
Displacement, Serum thyroxine (T4) from carrier protein |
leads to |
Increased, Free serum thyroxine (T4) |
2250 |
Binding, Thyroid binding globulin in serum |
leads to |
Displacement, Serum thyroxine (T4) from carrier protein |
2251 |
TLR4 activation |
leads to |
AP-1 activation |
2252 |
Activation, PPARα |
leads to |
Increase, cell proliferation (hepatocytes) |
2253 |
Activation, PPARα |
leads to |
Increase, hepatocellular adenomas and carcinomas |
2254 |
Increase, cell proliferation (hepatocytes) |
leads to |
Increase, hepatocellular adenomas and carcinomas |
2255 |
Inhibition of LS function. |
leads to |
Loss of alveolar capillary membrane integrity |
2256 |
Inhibition of LS function. |
leads to |
Reduced lung volume |
2257 |
Reduced lung volume |
leads to |
Immediate adverse lung effects |
2258 |
Loss of alveolar capillary membrane integrity |
leads to |
Immediate adverse lung effects |
2259 |
Loss of alveolar capillary membrane integrity |
leads to |
Substance - LS interaction |
2260 |
Agonism, Androgen receptor |
leads to |
Increased, Differentiation to Testis |
2261 |
Activation, Glucocorticoid Receptor |
leads to |
Up Regulation, CD36 |
2262 |
Up Regulation, CD36 |
leads to |
Increased, Fatty acid uptake |
2263 |
Increased, Fatty acid uptake |
leads to |
Increased, Liver Steatosis |
2264 |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
leads to |
Accumulation, Triglyceride |
2265 |
Accumulation, Triglyceride |
leads to |
Increased, Liver Steatosis |
2266 |
Activation, Glucocorticoid Receptor |
leads to |
Decrease, ACAD |
2267 |
Decrease, ACAD |
leads to |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
2268 |
Increased, Free serum thyroxine (T4) |
leads to |
Increased, Uptake of thyroxine into tissue |
2269 |
Binding, Transthyretin in serum |
leads to |
Increased, Clearance of thyroxine from serum |
2270 |
Increased, Clearance of thyroxine from serum |
leads to |
T4 in serum, Decreased |
2271 |
Binding, Transthyretin in serum |
leads to |
Increased, Free serum thyroxine (T4) |
2272 |
Increased, Free serum thyroxine (T4) |
leads to |
Increased, Clearance of thyroxine from serum |